

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 April 2003 (24.04.2003)

PCT

(10) International Publication Number
WO 03/033513 A1

(51) International Patent Classification⁷: C07H 21/02,
21/04, C07K 14/47, A61K 38/17, 48/00, A61P 3/00, 3/06,
C12Q 1/68

(21) International Application Number: PCT/AU02/01405

(22) International Filing Date: 16 October 2002 (16.10.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/330,149 16 October 2001 (16.10.2001) US

(71) Applicants (for all designated States except US): **AUTO-GEN RESEARCH PTY LTD** [AU/AU]; 439 Bay Street, North Brighton, Victoria 3186 (AU). **INTERNATIONAL DIABETES INSTITUTE** [AU/AU]; 260 Kooyong Road, Caulfield, Victoria 3162 (AU). **DEAKIN UNIVERSITY** [AU/AU]; Pigdons Road, Waurn Ponds, Victoria 3221 (AU). **WINDMILL, Kelly** [AU/AU]; 24 Cook Street, Newtown, Victoria 3220 (AU).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **COLLIER, Greg**

[AU/AU]; 22 Kestrel Place, Ocean Grove, Victoria 3226 (AU). **ZIMMET, Paul, Zev** [AU/AU]; 24 Linlithgow Road, Toorak, Victoria 3142 (AU). **WALDER, Ken** [AU/AU]; 54 Lake Avenue, Ocean Grove, Victoria 3226 (AU). **MCMILLAN, Janine** [AU/AU]; 5 Afzan Court, Torquay, Victoria 3228 (AU). **DE SILVA, Andrea, Michelle** [AU/AU]; 121 Aphrasia Street, Newtown, Victoria 3220 (AU).


(74) Agents: **HUGHES, E, John, L.** et al.; DAVIES COLLISON CAVE, Level 3, 303 Coronation Drive, Milton, Queensland 4064 (AU).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: DIFFERENTIALLY EXPRESSED GENES ASSOCIATED WITH OBESITY AND TYPE 2 DIABETES



(57) Abstract: The present invention relates to nucleic acid molecules which encode expression products associated with the modulation of obesity, anorexia, weight maintenance, diabetes and/or metabolic energy levels. The nucleic acid molecules and expression products of the present invention are produced by recombinant means or isolated from natural resources. The subject nucleic acid molecules and expression products and their derivatives, homologs, analogs and mimetics are proposed to be useful as therapeutic and diagnostic agents for obesity, anorexia, weight maintenance, diabetes and/or energy imbalance or as targets for the design and/or identification of modulators of their activity and/or function. The subject nucleic acid molecules and expression products are identified using differential display techniques.



WO 03/033513 A1



European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*

**DIFFERENTIALLY EXPRESSED GENES
ASSOCIATED WITH OBESITY AND TYPE 2 DIABETES**

FIELD OF THE INVENTION

5 The present invention relates generally to a nucleic acid molecule which expressed in at least the stomach, hypothalamus or liver identified using differential display techniques under differing physiological conditions. It is proposed that the nucleic acid molecules encode expression products associated with the modulation of obesity, anorexia, weight maintenance, diabetes and/or metabolic energy levels. More particularly, the present
10 invention is directed to nucleic acid molecules and expression products produced by recombinant means from the nucleic acid molecule or isolated from natural sources and their use in therapeutic and diagnostic protocols for conditions such as obesity, anorexia, weight maintenance, diabetes and/or energy imbalance. The subject nucleic acid molecule and expression products and their derivatives, homologs, analogs and mimetics are
15 proposed to be useful, therefore, as therapeutic and diagnostic agents for obesity, anorexia, weight maintenance, diabetes and/or energy imbalance or as targets for the design and/or identification of modulators of their activity and/or function.

BACKGROUND OF THE INVENTION

20

Bibliographic details of references provided in the subject specification are listed at the end of the specification.

Reference to any prior art in this specification is not, and should not be taken as, an
25 acknowledgment or any form of suggestion that this prior art forms part of the common general knowledge in any country.

The increasing sophistication of recombinant DNA technology is greatly facilitating research and development in the medical, veterinary and allied human and animal health
30 fields. This is particularly the case in the investigation of the genetic bases involved in the etiology of certain disease conditions. One particularly significant condition from the stand

- 2 -

point of morbidity and mortality is obesity and its association with type 2 diabetes (formerly non-insulin-dependent diabetes mellitus or NIDDM) and cardiovascular disease.

Obesity is defined as a pathological excess of body fat and is the result of an imbalance
5 between energy intake and energy expenditure for a sustained period of time. Obesity is
the most common metabolic disease found in affluent nations. The prevalence of obesity in
these nations is alarmingly high, ranging from 10% to upwards of 50% in some
subpopulations (Bouchard, *The genetics of obesity*. Boca Raton: CRC Press, 1994). Of
particular concern is the fact that the prevalence of obesity appears to be rising consistently
10 in affluent societies and is now increasing rapidly in less prosperous nations as they
become more affluent and/or adopt cultural practices from the more affluent countries
(Zimmet, *Diabetes Care* 15(2): 232-247, 1992).

In 1995 in Australia, for example, 19% of the adult population were obese (BMI>30). On
15 average, women in 1995 weighed 4.8 kg more than their counterparts in 1980 while men
weighed 3.6 kg more (Australian Institute of Health and Welfare, Heart, Stroke and
Vascular diseases, Australian facts. AIHW Cat. No. CVD 7 Canberra: AIHW and the
Heart Foundation of Australia, 1999). More recently, the AusDiab Study conducted
between the years 1999 and 2000 showed that 65% of males and 45% of females aged 25-
20 64 years were considered overweight (de Looper and Bhatia, *Australia's Health Trends*
2001. Australian Institute of Health and Welfare (AIHW) Cat. No. PHE 24. Canberra:
AIHW, 2001). The prevalence of obesity in the United States also increased substantially
between 1991 and 1998, rising from 12% to 18% in Americans during this period (Mokdad
et al., *JAMA*. 282(16): 1519-1522, 1999).

25

The high and increasing prevalence of obesity has serious health implications for both
individuals and society as a whole. Obesity is a complex and heterogeneous disorder and
has been identified as a key risk indicator of preventable morbidity and mortality since
obesity increases the risk of a number of other metabolic conditions including type 2
30 diabetes mellitus and cardiovascular disease (Must *et al.*, *JAMA*. 282(16): 1523-1529,
1999; Kopelman, *Nature* 404: 635-643, 2000). Alongside obesity, the prevalence of

diabetes continues to increase rapidly. It has been estimated that there were about 700,000 persons with diabetes in Australia in 1995 while in the US, diabetes prevalence increased from 4.9% in 1990 to 6.9% in 1999 (Mokdad, *Diabetes Care* 24(2): 412, 2001). In Australia, the annual costs of obesity associated with diabetes and other disease conditions has been conservatively estimated to be AU\$810 million for 1992-3 (National Health and Medical Research Council, Acting on Australia's weight: A strategy for the prevention of overweight and obesity. Canberra: National Health and Medical Research Council, 1996). In the U.S., the National Health Interview Survey (NHIS) estimated the economic cost of obesity in 1995 as approximately US\$99 billion, thereby representing 5.7% of total health costs in the U.S. at that time (Wolf and Colditz, *Obes Res.* 6: 97-106, 1998).

A genetic basis for the etiology of obesity is indicated *inter alia* from studies in twins, adoption studies and population-based analyses which suggest that genetic effects account for 25-80% of the variation in body weight in the general population (Bouchard, 1994, *supra*; Kopelman *et al.*, *Int J Obesity* 18: 188-191, 1994; Ravussin, *Metabolism* 44(Suppl 3): 12-14, 1995). It is considered that genes determine the possible range of body weight in an individual and then the environment influences the point within this range where the individual is located at any given time (Bouchard, 1994, *supra*). However, despite numerous studies into genes thought to be involved in the pathogenesis of obesity, there have been surprisingly few significant findings in this area. In addition, genome-wide scans in various population groups have not produced definitive evidence of the chromosomal regions having a major effect on obesity.

A number of organs/tissues have been implicated in the pathophysiology of obesity and type 2 diabetes, and of particular interest are the hypothalamus, stomach and liver. The hypothalamus has long been recognized as a key brain area in the regulation of energy intake (Stellar, *Psychol Rev* 61: 5-22, 1954) and it is now widely accepted that the hypothalamus plays a central role in energy homeostasis, integrating and co-ordinating a large number of factors produced by and/or acting on the hypothalamus. A number of these factors have been investigated for their role in energy balance and body weight regulation, including neuropeptide Y, corticotropin-releasing hormone, melanin-concentrating

- 4 -

hormone, leptin and insulin. It has been proposed that genetic alterations perturbing the metabolic pathways regulating energy balance in the hypothalamus could contribute to the development of obesity, and subsequently diabetes. Thus, an important step in understanding the function of the hypothalamus in regulating the metabolism of an animal
5 requires the identification of the targets of these hormones. Such targets may be whole organs, and genes whose expression is regulated by the presence of these hormones.

The role of the stomach in regulating food intake is thought to involve two types of signals: the degree of distension of the stomach and the activation of chemoreceptors in the
10 gastric or intestinal wall (Koopmans, Experimental studies on the control of food intake. In: Handbook of Obesity, Eds. GA Bray, C Bouchard, WPT James pp 273-312, 1998). The gut is the largest endocrine organ in the body and after a meal a large number of gastrointestinal hormones are released. Some examples are gastrin, somatostatin, cholecystokinin, gastric inhibitory polypeptide and neurotensin. Despite general agreement
15 that the stomach provides part of the signal that restricts food intake during a single meal, the nature of this signal or how it is transmitted to the brain remains to be determined. Most likely the information relating to the degree of distension of the stomach or the presence of nutrients in the gastrointestinal walls is transmitted to the brain through either nerves or hormones. The role of the gut hormones identified to date in the regulation of
20 food intake remains to be equivocally determined.

The liver also plays a significant role in a number of important physiological pathways. It has a major role in the regulation of metabolism of glucose, amino acids and fat. In addition the liver is the only organ (other than the gut) that comes into direct contact with a
25 large volume of ingested, absorbed food *via* the portal vein and, therefore, the liver is able to “sense” or monitor the level of nutrients entering the body, particularly the amounts of protein and carbohydrate. It has been proposed that the liver may also have a role in the regulation of food intake through the transmission of unidentified signals relaying information to the brain about nutrient absorption from the gut and metabolic changes
30 throughout the body (Russek, *Nature* 200: 176, 1963). The liver also plays a crucial role in maintaining circulating glucose concentrations by regulating pathways such as

- 5 -

gluconeogenesis and glycogenolysis. Alterations in glucose homeostasis are important factors in the pathophysiology of impaired glucose tolerance and the development of type 2 diabetes mellitus.

- 5 In accordance with the present invention, genetic sequences were sought which are differentially expressed in particular vertebrate animal tissues or organs between either fed, re-fed or fasting conditions, or between diabetic and non-diabetic conditions. Novel genes are identified which are differentially expressed at least in the stomach, liver and/or hypothalamus under one or both of the above-mentioned conditions. In accordance with
- 10 the present invention, the inventors have isolated genes which are proposed to be associated with one or more biological functions associated with disease conditions such as but not limited to obesity, anorexia, diabetes or energy balance.

SUMMARY OF THE INVENTION

Throughout this specification, unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

Nucleotide and amino acid sequences are referred to by a sequence identifier number (SEQ ID NO:). The SEQ ID NOs: correspond numerically to the sequence identifiers <400>1 (SEQ ID NO:1), <400>2 (SEQ ID NO:2), etc. A summary of the sequence identifiers is provided in Table 1. A sequence listing is provided after the claims.

Analysis of genetic material from stomach, hypothalamus and liver tissue were used to identify candidate genetic sequences associated with a healthy state or with physiological conditions such as obesity, anorexia, weight maintenance, diabetes and/or metabolic energy levels. An animal model was employed comprising the Israeli Sand Rat (*Psammomys obesus*). Three groups of animals were used designated Groups A, B and C based on metabolic phenotype as follows:-

- 20 Group A: lean animals (normoglycemic; normoinsulinemic);
- Group B: obese, non-diabetic animals (normoglycemic; hyperinsulinemic); and
- Group C: obese, diabetic animals (hyperglycemic; hyperinsulinemic).

Techniques including differential display PCR analysis, suppression subtractive hybridization (SSH) and amplified fragment length polymorphism analysis of mRNA from stomach, liver or hypothalamus tissue were used to identify genetic sequences differentially expressed in fed, re-fed and fasted mammals or in diabetic and non-diabetic mammals. The Israeli Sand Rat (*Psammomys obesus*) was found to be particularly useful for this analysis. In a preferred embodiment, seven differentially expressed sequences were identified designated herein *AGT-119* [SEQ ID NO:1], *AGT-120* [SEQ ID NO:2], *AGT-121* [SEQ ID NO:3], *AGT-122* [SEQ ID NO:5], *AGT-422* [SEQ ID NO:6], *AGT-123* [SEQ

- 7 -

ID NO:7] and *AGT-504* [SEQ ID NO:8 and SEQ ID NO:9]. SEQ ID NO:9 is a genomic form of *AGT-504* and is also represented as SEQ ID NO:8.

AGT-119 was detected initially in stomach tissue using differential display PCR and its
5 expression was elevated in fed animals compared to fasted or re-fed animals. *AGT-120* was
initially detected in stomach tissue using differential display PCR and its expression was
elevated in fed animals compared to fasted or re-fed animals. *AGT-121* was initially
identified in the hypothalamus using differential display PCR and its expression levels
were elevated in fasted diabetic, non-diabetic and lean animals compared to fed animals
10 when separated by genotype. *AGT-122* was initially identified in the liver using differential
display PCR and was shown to have elevated expression levels in fasted compared to fed
diabetic or non-diabetic animals. *AGT-422* was identified suppression subtractive
hybridization in liver tissue and its expression was elevated in fed lean animals compared
to fed diabetic animals and elevated in fed, lean animals compared to fasted lean animals,
15 in fed non-diabetic animals compared to fasted non-diabetic animals and fed diabetic
animals compared to fasted diabetic animals. *AGT-123* was identified in the hypothalamus
tissue using differential display PCR and its expression was found to be elevated in fasted
lean, non-diabetic animals and diabetic animals compared to fed animals. *AGT-504* was
identified using amplified fragment length polymorphism analysis in genomic DNA and its
20 expression in liver tissue was elevated in diabetic animals compared to lean or non-diabetic
animals. A summary of the AGT genes is provided in Table 1.

- 8 -

TABLE 1
Summary of Differentially Expressed Genes

GENE	SEQ ID NO:	TISSUE	CHARACTERISTICS	DETECTION METHOD
<i>AGT-119</i>	1	stomach	elevated expression in fed animals compared to fasted or re-fed animals	differential display PCR
<i>AGT-120</i>	2	stomach	elevated expression in fed animals compared to fasted or re-fed animals	differential display PCR
<i>AGT-121</i>	3 and 4	hypothalamus	elevated expression in fasted diabetic, non-diabetic and lean animals compared to fed animals when separated by genotype.	differential display PCR
<i>AGT-122</i>	5	liver	elevated expression in fasted compared to fed diabetic and non-diabetic animals	differential display PCR
<i>AGT-422</i>	6	liver	elevated expression in fed lean animals compared to fed diabetic animals and elevated expression in fed lean animals compared to fasted lean animals, in fed non-diabetic animals compared to fasted non-diabetic animals and fed diabetic animals compared to fasted diabetic animals	suppression subtractive hybridization (representational difference analysis)
<i>AGT-123</i>	7	hypothalamus	elevated expression in fasted lean, non-diabetic and diabetic animals compared to fed animals	differential display PCR
<i>AGT-504</i>	8 (genomic) and 9 (cDNA)	liver	elevated expression in diabetic animals compared to lean or non-diabetic animals	amplified fragment length polymorphism analysis

- 9 -

The present invention provides, therefore, a nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding an expression product or a derivative, homolog, analog or mimetic thereof wherein said nucleic acid molecule is
5 differentially expressed in one or more of stomach, liver or hypothalamus tissue under fed or unfed or diabetic or non-diabetic conditions.

The present invention further provides a nucleic acid molecule comprising a nucleotide
10 sequence encoding or complementary to a sequence encoding an expression product or a derivative, homolog, analog or mimetic thereof wherein the nucleotide sequence is as substantially set forth in SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 or a nucleotide
15 sequence having at least about 30% similarity to all or part of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 and/or is capable of hybridizing to one or more of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or
20 SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 or their complementary forms under low stringency conditions at 42°C and wherein the nucleic acid molecule is differentially expressed in one or more of stomach, liver or hypothalamus tissue under fed or unfed or diabetic or non-diabetic conditions.

The present invention also provides an isolated expression product or a derivative, homolog, analog or mimetic thereof which expression product is encoded by a nucleotide
25 sequence which is differentially expressed in one or more of stomach, liver or hypothalamus tissue under fed or unfed or diabetic or non-diabetic conditions.

More particularly, the present invention is directed to an isolated expression product or a derivative, homolog, analog or mimetic thereof wherein the expression product is encoded
30 by a nucleotide sequence substantially as set forth in SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 or a nucleotide sequence having at least 30% similarity to all or part of SEQ ID

- 10 -

NO:1, SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7
or SEQ ID NO:8 or SEQ ID NO:9 and/or is capable of hybridizing to SEQ ID NO:1, SEQ
ID NO:2 or SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID
NO:8 or SEQ ID NO:9 or their complementary forms under low stringency conditions at
5 42°C.

The preferred genetic sequence of the present invention are referred to herein as *AGT-119*,
AGT-120, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504*. The expression products
encoded by *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504*
10 are referred to herein as AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123
and AGT-504, respectively. The expression product may be an RNA (e.g. mRNA) or a
protein. Where the expression product is an RNA, the present invention extends to RNA-
related molecules associated thereto such as RNAi or intron or exon sequences therefrom.

15 Even yet another aspect of the present invention relates to a composition comprising AGT-
119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and/or AGT-504 or its
derivatives, homologs, analogs or mimetics or agonists or antagonists of AGT-119, AGT-
120, AGT-121, AGT-122, AGT-422, AGT-123 and/or AGT-504 together with one or
more pharmaceutically acceptable carriers and/or diluents.

20

Another aspect of the present invention contemplates a method for treating a subject
comprising administering to said subject a treatment effective amount of AGT-119, AGT-
120, AGT-121, AGT-122, AGT-422, AGT-123 and/or AGT-504 or a derivative, homolog,
analog or mimetic thereof or a genetic sequence encoding same or an agonist or antagonist
25 of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and/or AGT-504
activity or *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504*
gene expression for a time and under conditions sufficient to effect treatment.

In accordance with this and other aspects of the present invention, treatments contemplated
30 herein include but are not limited to obesity, anorexia, weight maintenance, energy
imbalance and diabetes. Treatment may be by the administration of a pharmaceutical

- 11 -

composition or genetic sequences *via* gene therapy. Treatment is contemplated for human subjects as well as animals such as animals important to livestock industry.

A further aspect of the present invention is directed to a diagnostic agent for use in
5 monitoring or diagnosing conditions such as but not limited to obesity, anorexia, weight maintenance, energy imbalance and/or diabetes, said diagnostic agent selected from an antibody to AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 or AGT-504 or its derivatives, homologs, analogs or mimetics and a genetic sequence comprising or
10 capable of annealing to a nucleotide strand associated with *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* or *AGT-504* useful *inter alia* in PCR, hybridization, RFLP analysis or AFLP analysis.

- 12 -

A summary of sequence identifiers used throughout the subject specification is provided in Table 2.

TABLE 2

5

SEQUENCE ID NO:	DESCRIPTION
1	Nucleotide sequence of <i>AGT-119</i>
2	Nucleotide sequence of <i>AGT-120</i>
3	Nucleotide sequence of <i>AGT-121</i>
4	Corresponding amino acid of SEQ ID NO:3
5	Nucleotide sequence of <i>AGT-122</i>
6	Nucleotide sequence of <i>AGT-422</i>
7	Nucleotide sequence of <i>AGT-123</i>
8	Nucleotide sequence of <i>AGT-504</i> (genomic)
9	Nucleotide sequence of <i>AGT-504</i> (cDNA)
10	primer
11	primer
12	<i>AGT-119</i> (set 1) forward primer
13	<i>AGT-119</i> (set 1) reverse primer
14	<i>AGT-119</i> (set 2) forward primer
15	<i>AGT-119</i> (set 2) reverse primer
16	<i>AGT-120</i> forward primer
17	<i>AGT-120</i> reverse primer
18	<i>AGT-121</i> forward (insertion) primer
19	<i>AGT-121</i> forward (deletion) primer
20	<i>AGT-121</i> reverse primer
21	<i>AGT-122</i> forward primer
22	<i>AGT-122</i> reverse primer
23	<i>AGT-422</i> forward primer
24	<i>AGT-422</i> reverse primer

- 13 -

SEQUENCE ID NO:	DESCRIPTION
25	<i>AGT-123</i> forward primer
26	<i>AGT-123</i> reverse primer
27	<i>AGT-504</i> forward primer
28	<i>AGT-504</i> reverse primer
29	β -actin forward primer
30	β -actin reverse primer
31	β -actin probe
32	Cyclophilin forward primer
33	Cyclophilin reverse primer
34	Cyclophilin probe

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graphical representation showing *AGT-119* stomach gene expression in fed, fasted and re-fed *Psammomys obesus*.

5

Figure 2 is a graphical representation of *AGT-120* stomach gene expression in fasted, fed and re-fed *Psammomys obesus*.

Figure 3 is a graphical representation showing the distribution of tissue in which *AGT-121* is expressed.

10

Figure 4 is a photographic representation showing Northern analysis of *AGT-121* expression in (1) heart; (2) brain; (3) placenta; (4) lung; (5) liver; (6) skeletal muscle); (7) kidney and (8) pancreas.

15

Figure 5 is a graphical representation showing *AGT-121* expression in energy restricted hypothalamus.

Figure 6 is a graphical representation showing expression of *AGT-121* versus level of body weight.

20

Figure 7 is a graphical representation showing expression of *AGT-121* versus change in glucose levels.

25 **Figure 8** graphical representation showing expression of *AGT-121* versus scap fat.

Figure 9 is a graphical representation of *AGT-122* hepatic gene expression in Groups A, B and C fed and fasted *Psammomys obesus*.

30 **Figure 10** is a graphical representation of *AGT-122* hepatic gene expression for fed and fasted *Psammomys obesus*(pooled data) .

Figure 11 is a graphical representation of the association between *AGT-122* hepatic gene expression and body weight in fed *Psammomys obesus*.

5 **Figure 12** is a graphical representation of *AGT-422* hepatic gene expression data from Groups A, B and C fed and fasted *Psammomys obesus*.

Figure 13 is a graphical representation of *AGT-422* hepatic gene expression in all fed and fasted *Psammomys obesus* (pooled data).

10

Figure 14 is a graphical representation of *AGT-123* hypothalamic gene expression in Groups A, B and C fed and fasted *Psammomys obesus*.

15 **Figure 15** is a graphical representation of *AGT-504* hepatic gene expression in Groups A, B and C *Psammomys obesus*.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is predicated in part on the identification of novel genes associated *inter alia* with regulation of obesity, anorexia, weight maintenance, diabetes and/or metabolic energy levels. The genes are identified following differential screening of mRNA from one or more of stomach, liver or hypothalamus tissue in fed, re-fed and fasted mammals or in diabetic and non-diabetic mammals. The selection of stomach, liver and hypothalamus is not intended to imply that differential expression does not occur in other tissue.

10

Accordingly, one aspect of the present invention provides a nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding an expression product or a derivative, homolog, analog or mimetic thereof wherein said nucleic acid molecule is differentially expressed in one or more of stomach, liver or hypothalamus tissue under fed (or re-fed) or unfed or diabetic or non-diabetic conditions.

15

The term “differentially expressed” is used in its most general sense and includes elevated levels of an expression product such as mRNA or protein or a secondary product such as cDNA in one tissue compared to another tissue or in the same tissue but under different conditions. Examples of different conditions includes differential expression in tissue from fed, re-fed and fasting animals or diabetic and non-diabetic animals. Differential expression is conveniently determined by a range of techniques including polymerase chain reaction (PCR) such as real-time PCR. Other techniques include suppression subtractive hybridization (SSH) and amplified fragment length polymorphism (AFLP) analysis.

20
25

Conveniently, an animal model may be employed to study the differences in gene expression in animal tissues under different conditions. In particular, the present invention is exemplified using the *Psammomys obesus* (the Israeli Sand Rat) animal model of dietary-induced obesity and type 2 diabetes. In their natural desert habitat, an active lifestyle and saltbush diet ensure that they remain lean and normoglycemic (Shafrir and

30

- 17 -

Gutman, *J. Basic Clin. Physiol. Pharm.* 4: 83-99, 1993). However, in a laboratory setting on a diet of *ad libitum* chow (on which many other animal species remain healthy), a range of pathophysiological responses are seen (Barnett *et al.*, *Diabetologia* 37: 671-676, 1994a; Barnett *et al.*, *Int. J. Obesity* 18: 789-794, 1994b; Barnett *et al.*, *Diabete Nutr. Metab.* 8: 5 42-47, 1995). By the age of 16 weeks, more than half of the animals become obese and approximately one third develop type 2 diabetes. Only hyperphagic animals go on to develop hyperglycemia, highlighting the importance of excessive energy intake in the pathophysiology of obesity and type 2 diabetes in *Psammomys obesus* (Collier *et al.*, *Ann. New York Acad. Sci.* 827: 50-63, 1997a; Walder *et al.*, *Obesity Res.* 5: 193-200, 1997a). 10 Other phenotypes found include hyperinsulinemia, dyslipidemia and impaired glucose tolerance (Collier *et al.*, 1997a, *supra*; Collier *et al.*, *Exp. Clin. Endocrinol. Diabetes* 105: 36-37, 1997b). *Psammomys obesus* exhibit a range of bodyweight and blood glucose and insulin levels which form a continuous curve that closely resembles the patterns found in human populations, including the inverted U-shaped relationship between blood glucose 15 and insulin levels known as “Starling’s curve of the pancreas” (Barnett *et al.*, 1994a, *supra*). It is the heterogeneity of the phenotypic response of *Psammomys obesus* which makes it an ideal model to study the etiology and pathophysiology of obesity and type 2 diabetes.

20 The animals are conveniently classified into three groups designated Groups A, B and C:

- Group A: animals are lean;
- Group B: animals are obese and non-diabetic; and
- Group C: animals are obese and diabetic.

25

In accordance with the present invention, a number of differentially expressed genetic sequences were identified in stomach, liver or hypothalamus tissue in *Psammomys obesus* under different feeding regimes (i.e. fed, re-fed or fasting) or under diabetic or non-diabetic conditions.

30

Another aspect of the present invention provides a nucleic acid molecule comprising a

- 18 -

nucleotide sequence encoding or complementary to a sequence encoding an expression product or a derivative, homolog, analog or mimetic thereof wherein said nucleotide sequence is as substantially set forth in SEQ ID NO:1 (AGT-119) or SEQ ID NO:2 (AGT-120) or SEQ ID NO:3 (AGT-121) or SEQ ID NO:5 (AGT-122) or SEQ ID NO:6 (AGT-422) or SEQ ID NO:7 (AGT-123) or SEQ ID NO:8 (AGT-504 genomic) or SEQ ID NO:9 (AGT-504 cDNA) or a nucleotide sequence having at least about 30% similarity to all or part of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 and/or is capable of hybridizing to one or more of SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:4 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 or their complementary forms under low stringency conditions at 42°C and wherein said nucleic acid molecule is differentially expressed in one or more of stomach, liver or hypothalamus tissue under fed or unfed or diabetic or non-diabetic conditions.

Higher similarities are also contemplated by the present invention such as greater than about 40% or 50% or 60% or 70% or 80% or 90% or 95% or 96% or 97% or 98% or 99% or above.

An expression product includes an RNA molecule such as an mRNA transcript as well as a protein. Some genes are non-protein encoding genes and produce mRNA or other RNA molecules and are involved in regulation by RNA:DNA, RNA:RNA or RNA:protein interaction. The RNA (e.g. mRNA) may act directly or *via* the induction of other molecules such as RNAi or *via* products mediated from splicing events (e.g. exons or introns). Other genes encode mRNA transcripts which are then translated into proteins. A protein includes a polypeptide. The differentially expressed nucleic acid molecules, therefore, may encode mRNAs only or, in addition, proteins. Both mRNAs and proteins are forms of "expression products".

Reference herein to similarity is generally at a level of comparison of at least 15 consecutive or substantially consecutive nucleotides. It is particularly convenient, however, to determine similarity by comparing a total or complete sequence, after optimal

- 19 -

alignment.

The term "similarity" as used herein includes exact identity between compared sequences at the nucleotide level. Where there is non-identity at the nucleotide level, "similarity" includes differences between sequences which may encode different amino acids that are nevertheless related to each other at the structural, functional, biochemical and/or conformational levels. In a particularly preferred embodiment, nucleotide sequence comparisons are made at the level of identity rather than similarity.

10 Terms used to describe sequence relationships between two or more polynucleotides include "reference sequence", "comparison window", "sequence similarity", "sequence identity", "percentage of sequence similarity", "percentage of sequence identity", "substantially similar" and "substantial identity". A "reference sequence" is at least 12 but frequently 15 to 18 and often at least 25 or above, such as 30 monomer units in length.

15 Because two polynucleotides may each comprise (1) a sequence (i.e. only a portion of the complete polynucleotide sequence) that is similar between the two polynucleotides, and (2) a sequence that is divergent between the two polynucleotides, sequence comparisons between two (or more) polynucleotides are typically performed by comparing sequences of the two polynucleotides over a "comparison window" to identify and compare local

20 regions of sequence similarity. A "comparison window" refers to a conceptual segment of typically 12 contiguous residues that is compared to a reference sequence. The comparison window may comprise additions or deletions (i.e. gaps) of about 20% or less as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. Optimal alignment of sequences for aligning a comparison

25 window may be conducted by computerized implementations of algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package Release 7.0, Genetics Computer Group, 575 Science Drive Madison, WI, USA) or by inspection and the best alignment (i.e. resulting in the highest percentage homology over the comparison window) generated by any of the various methods selected. Reference also

30 may be made to the BLAST family of programs as for example disclosed by Altschul *et al.* (*Nucl. Acids Res.* 25: 3389, 1997). A detailed discussion of sequence analysis can be found

- 20 -

in Unit 19.3 of Ausubel *et al.* ("Current Protocols in Molecular Biology" John Wiley & Sons Inc, Chapter 15, 1994-1998). A range of other algorithms may be used to compare the nucleotide and amino acid sequences such as but not limited to PILEUP, CLUSTALW, SEQUENCHER or VectorNTI.

5

The terms "sequence similarity" and "sequence identity" as used herein refers to the extent that sequences are identical or functionally or structurally similar on a nucleotide-by-nucleotide basis over a window of comparison. Thus, a "percentage of sequence identity", for example, is calculated by comparing two optimally aligned sequences over the window
10 of comparison, determining the number of positions at which the identical nucleic acid base (e.g. A, T, C, G, I) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. For the purposes of the present invention, "sequence
15 identity" will be understood to mean the "match percentage" calculated by the DNASIS computer program (Version 2.5 for windows; available from Hitachi Software engineering Co., Ltd., South San Francisco, California, USA) using standard defaults as used in the reference manual accompanying the software. Similar comments apply in relation to sequence similarity.

20

Reference herein to a low stringency includes and encompasses from at least about 0 to at least about 15% v/v formamide and from at least about 1 M to at least about 2 M salt for hybridization, and at least about 1 M to at least about 2 M salt for washing conditions. Generally, low stringency is at from about 25-30°C to about 42°C. The temperature may
25 be altered and higher temperatures used to replace formamide and/or to give alternative stringency conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5 M to at least about 0.9 M salt for hybridization, and at least about 0.5 M to at least about 0.9 M salt for washing
30 conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01 M to at least about

- 21 -

0.15 M salt for hybridization, and at least about 0.01 M to at least about 0.15 M salt for washing conditions. In general, washing is carried out $T_m = 69.3 + 0.41 (G+C)\%$ (Marmur and Doty, *J. Mol. Biol.* 5: 109, 1962). However, the T_m of a duplex DNA decreases by 1°C with every increase of 1% in the number of mismatch base pairs (Bonner and Laskey, *Eur. J. Biochem.* 46: 83, 1974). Formamide is optional in these hybridization conditions. Accordingly, particularly preferred levels of stringency are defined as follows: low stringency is 6 x SSC buffer, 0.1% w/v SDS at 25-42°C; a moderate stringency is 2 x SSC buffer, 0.1% w/v SDS at a temperature in the range 20°C to 65°C; high stringency is 0.1 x SSC buffer, 0.1% w/v SDS at a temperature of at least 65°C.

10

The nucleotide sequence or amino acid sequence of the present invention may correspond to exactly the same sequence of the naturally occurring gene (or corresponding cDNA) or protein or other expression product or may carry one or more nucleotide or amino acid substitutions, additions and/or deletions. The nucleotide sequences set forth in SEQ ID NO:1 (AGT-119), SEQ ID NO:2 (AGT-120) and SEQ ID NO:3 (AGT-121) or SEQ ID NO:5 (AGT-122) or SEQ ID NO:6 (AGT-422) or SEQ ID NO:7 (AGT-123) or SEQ ID NO:8 (AGT-504 genomic) or SEQ ID NO:9 (AGT-504 cDNA) correspond to novel genes referred to in parenthesis. The corresponding expression products are AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504. Reference herein to *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* includes, where appropriate, reference to the genomic gene or cDNA as well as any naturally occurring or induced derivatives. For example, a genomic form of AGT-504 is represented as SEQ ID NO:8. Apart from the substitutions, deletions and/or additions to the nucleotide sequence, the present invention further encompasses mutants, fragments, parts and portions of the nucleotide sequence corresponding to *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504*.

25

Another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:1 (AGT-119) or a

30

- 22 -

derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:1 or a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or its complementary form under low stringency conditions.

5 Yet another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:2 (AGT-120) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or
10 part of SEQ ID NO:2 or a nucleotide sequence capable of hybridizing to SEQ ID NO:2 or its complementary form under low stringency conditions.

Still yet another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a
15 nucleotide sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:3 (AGT-121) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:3 or a nucleotide sequence capable of hybridizing to SEQ ID NO:3 or their complementary forms under low stringency conditions.

20

Even yet another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:5 (AGT-122)
25 or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:5 or a nucleotide sequence capable of hybridizing to SEQ ID NO:5 or its complementary form under low stringency conditions.

Even still another aspect of the present invention provides a nucleic acid molecule or
30 derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product

- 23 -

wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:6 (AGT-422) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:6 or a nucleotide sequence capable of hybridizing to SEQ ID NO:6 or its complementary form under low stringency conditions.

5

Another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:7 (AGT-123) or a
10 derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:7 or a nucleotide sequence capable of hybridizing to SEQ ID NO:7 or its complementary form under low stringency conditions.

A further aspect of the present invention provides a nucleic acid molecule or derivative,
15 homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said nucleotide sequence is substantially as set forth in SEQ ID NO:8 (AGT-504 genomic) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:8 or a nucleotide sequence capable of hybridizing to SEQ ID NO:8 or
20 its complementary form under low stringency conditions.

Yet another aspect of the present invention provides a nucleic acid molecule or derivative, homolog or analog thereof comprising a nucleotide sequence encoding, or a nucleotide sequence complementary to a sequence encoding an expression product wherein said
25 nucleotide sequence is substantially as set forth in SEQ ID NO:9 (AGT-504 cDNA) or a derivative, homolog or mimetic thereof or having at least about 30% similarity to all or part of SEQ ID NO:9 or a nucleotide sequence capable of hybridizing to SEQ ID NO:9 or its complementary form under low stringency conditions.

30 The expression pattern of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* has been determined, *inter alia*, to indicate an involvement in the regulation

- 24 -

of one or more of obesity, anorexia, weight maintenance, diabetes and/or energy metabolism. In addition to the differential expression of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* in one or more of stomach, liver or hypothalamus tissue of fed *versus* fasted or diabetic *versus* non-diabetic animals, these
5 genes may also be expressed in other tissues including but in no way limited to brain, muscle, adipose tissue, pancreas and gastrointestinal tract. The nucleic acid molecule encoding each of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* or *AGT-504* is preferably a DNA such as a cDNA sequence or a genomic DNA. A genomic sequence may also comprise exons and introns. A genomic sequence may also include a
10 promoter region or other regulatory regions.

A homolog is considered to be a gene from another animal species which has the same or greater than 30% similarity to one of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* and/or which has a similar function. The above-mentioned genes
15 are exemplified herein from *Psammomys obesus* stomach, liver or hypothalamus. The present invention extends, however, to the homologous gene, as determined by nucleotide sequence and/or function, from humans, primates, livestock animals (e.g. cows, sheep, pigs, horses, donkeys), laboratory test animals (e.g. mice, guinea pigs, hamsters, rabbits), companion animals (e.g. cats, dogs) and captured wild animals (e.g. rodents, foxes, deer,
20 kangaroos).

The nucleic acids of the present invention and in particular *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* and their derivatives and homologs may be in isolated or purified form and/or may be ligated to a vector such as an expression vector.
25 Expression may be in a eukaryotic cell line (e.g. mammalian, insect or yeast cells) or in prokaryote cells (e.g. *E. coli*) or in both. By "isolated" is meant a nucleic acid molecule having undergone at least one purification step and this is conveniently defined, for example, by a composition comprising at least about 10% subject nucleic acid molecule, preferably at least about 20%, more preferably at least about 30%, still more preferably at
30 least about 40-50%, even still more preferably at least about 60-70%, yet even still more preferably 80-90% or greater of subject nucleic acid molecule relative to other components

- 25 -

as determined by molecular weight, encoding activity, nucleotide sequence, base composition or other convenient means. The nucleic acid molecule of the present invention may also be considered, in a preferred embodiment, to be biologically pure. The nucleic acid molecule may be ligated to an expression vector capable of expression in a
5 prokaryotic cell (e.g. *E. coli*) or a eukaryotic cell (e.g. yeast cells, fungal cells, insect cells, mammalian cells or plant cells). The nucleic acid molecule may be ligated or fused or otherwise associated with a nucleic acid molecule encoding another entity such as, for example, a signal peptide. It may also comprise additional nucleotide sequence information fused, linked or otherwise associated with it either at the 3' or 5' terminal portions or at
10 both the 3' and 5' terminal portions. The nucleic acid molecule may also be part of a vector, such as an expression vector.

The derivatives of the nucleic acid molecule of the present invention include oligonucleotides, PCR primers, antisense molecules, molecules suitable for use in co-
15 suppression and fusion nucleic acid molecules. Ribozymes and DNAzymes are also contemplated by the present invention directed to *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* or their mRNAs. Derivatives and homologs of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* are conveniently encompassed by those nucleotide sequences capable of hybridizing to one or
20 more of SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 or their complementary forms under low stringency conditions.

Derivatives include fragments, parts, portions, mutants, variants and mimetics from
25 natural, synthetic or recombinant sources including fusion nucleic acid molecules. Derivatives may be derived from insertion, deletion or substitution of nucleotides.

Another aspect of the present invention provides an isolated expression product or a derivative, homolog, analog or mimetic thereof which is produced in larger or lesser
30 amounts in one or more of stomach, liver or hypothalamus tissue in obese animals

- 26 -

compared to lean animals or in fed (including re-fed) compared to fasted animals or in animals under diabetic compared to non-diabetic conditions.

An expression product, as indicated above, may be RNA or protein. Insofar as the product
5 is a protein, derivatives include amino acid insertional derivatives such as amino and/or
carboxylic terminal fusions as well as intra-sequence insertions of single or multiple amino
acids. Insertional amino acid sequence variants are those in which one or more amino acid
residues are introduced into a predetermined site in a protein although random insertion is
also possible with suitable screening of the resulting product. Deletional variants are
10 characterized by the removal of one or more amino acids from the sequence. Substitutional
amino acid variants are those in which at least one residue in the sequence has been
removed and a different residue inserted in its place. An example of substitutional amino
acid variants are conservative amino acid substitutions. Conservative amino acid
substitutions typically include substitutions within the following groups: glycine and
15 alanine; valine, isoleucine and leucine; aspartic acid and glutamic acid; asparagine and
glutamine; serine and threonine; lysine and arginine; and phenylalanine and tyrosine.
Additions to amino acid sequences include fusions with other peptides, polypeptides or
proteins.

20 Chemical and functional equivalents of protein forms of the expression products AGT-119,
AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 or AGT-504 should be understood as
molecules exhibiting any one or more of the functional activities of these molecules and
may be derived from any source such as being chemically synthesized or identified *via*
screening processes such as natural product screening or screening of chemical libraries.

25

The derivatives include fragments having particular epitopes or parts of the entire protein
fused to peptides, polypeptides or other proteinaceous or non-proteinaceous molecules.

Reference herein to AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 or
30 AGT-504 includes reference to isolated or purified naturally occurring AGT-119, AGT-
120, AGT-121, AGT-122, AGT-422, AGT-123 or AGT-504 as well as any derivatives,

- 27 -

homologs, analogs and mimetics thereof. Derivatives include parts, fragments and portions of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 as well as single and multiple amino acid substitutions, deletions and/or additions to AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 when the expression
5 products are proteins. A derivative of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 or AGT-504 is conveniently encompassed by molecules encoded by a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or SEQ ID NO:2 or SEQ ID NO:3 or SEQ ID NO:5 or SEQ ID NO:6 or SEQ ID NO:7 or SEQ ID NO:8 or SEQ ID NO:9 under low stringency conditions.

10

Other derivatives of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 include chemical analogs. Analogs of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 contemplated herein include, but are not limited to, modifications to side chains, incorporation of unnatural amino acids and/or their
15 derivatives during peptide, polypeptide or protein synthesis and the use of crosslinkers and other methods which impose confirmational constraints on the proteinaceous molecule or their analogs.

Examples of side chain modifications contemplated by the present invention include
20 modifications of amino groups such as by reductive alkylation by reaction with an aldehyde followed by reduction with NaBH_4 ; amidination with methylacetimidate; acylation with acetic anhydride; carbamoylation of amino groups with cyanate; trinitrobenzylation of amino groups with 2, 4, 6-trinitrobenzene sulfonic acid (TNBS); acylation of amino groups with succinic anhydride and tetrahydrophthalic anhydride; and
25 pyridoxylation of lysine with pyridoxal-5-phosphate followed by reduction with NaBH_4 .

The guanidine group of arginine residues may be modified by the formation of heterocyclic condensation products with reagents such as 2,3-butanedione, phenylglyoxal and glyoxal.

30

- 28 -

The carboxyl group may be modified by carbodiimide activation *via* O-acylisourea formation followed by subsequent derivitization, for example, to a corresponding amide.

5 Sulphydryl groups may be modified by methods such as carboxymethylation with iodoacetic acid or iodoacetamide; performic acid oxidation to cysteic acid; formation of a mixed disulphides with other thiol compounds; reaction with maleimide, maleic anhydride or other substituted maleimide; formation of mercurial derivatives using 4-chloromercuribenzoate, 4-chloromercuriphenylsulphonic acid, phenylmercury chloride, 2-chloromercuri-4-nitrophenol and other mercurials; carbamoylation with cyanate at alkaline
10 pH.

Tryptophan residues may be modified by, for example, oxidation with N-bromosuccinimide or alkylation of the indole ring with 2-hydroxy-5-nitrobenzyl bromide or sulphenyl halides. Tyrosine residues on the other hand, may be altered by nitration with
15 tetranitromethane to form a 3-nitrotyrosine derivative.

Modification of the imidazole ring of a histidine residue may be accomplished by alkylation with iodoacetic acid derivatives or N-carbethoxylation with diethylpyrocarbonate.
20

Examples of incorporating unnatural amino acids and derivatives during peptide synthesis include, but are not limited to, use of norleucine, 4-amino butyric acid, 4-amino-3-hydroxy-5-phenylpentanoic acid, 6-aminohexanoic acid, t-butylglycine, norvaline, phenylglycine, ornithine, sarcosine, 4-amino-3-hydroxy-6-methylheptanoic acid, 2-thienyl
25 alanine and/or D-isomers of amino acids. A list of unnatural amino acid, contemplated herein is shown in Table 3.

TABLE 3
Codes for non-conventional amino acids

	Non-conventional amino acid	Code	Non-conventional amino acid	Code
5	α -aminobutyric acid	Abu	L-N-methylalanine	Nmala
	α -amino- α -methylbutyrate	Mgabu	L-N-methylarginine	Nmarg
10	aminocyclopropane-carboxylate	Cpro	L-N-methylasparagine	Nmasn
	aminoisobutyric acid	Aib	L-N-methylaspartic acid	Nmasp
	aminonorbornyl-carboxylate	Norb	L-N-methylcysteine	Nmcys
			L-N-methylglutamine	Nmgln
			L-N-methylglutamic acid	Nmglu
15	cyclohexylalanine	Chexa	L-N-methylhistidine	Nmhis
	cyclopentylalanine	Cpen	L-N-methylisoleucine	Nmile
	D-alanine	Dal	L-N-methylleucine	Nmleu
	D-arginine	Darg	L-N-methyllysine	Nmlys
	D-aspartic acid	Dasp	L-N-methylmethionine	Nmmet
20	D-cysteine	Dcys	L-N-methylnorleucine	Nmnle
	D-glutamine	Dgln	L-N-methylnorvaline	Nmnva
	D-glutamic acid	Dglu	L-N-methylornithine	Nmorn
	D-histidine	Dhis	L-N-methylphenylalanine	Nmphe
	D-isoleucine	Dile	L-N-methylproline	Nmpro
25	D-leucine	Dleu	L-N-methylserine	Nmser
	D-lysine	Dlys	L-N-methylthreonine	Nmthr
	D-methionine	Dmet	L-N-methyltryptophan	Nmtrp
	D-ornithine	Dorn	L-N-methyltyrosine	Nmtyr
	D-phenylalanine	Dphe	L-N-methylvaline	Nmval
30	D-proline	Dpro	L-N-methylethylglycine	Nmetg
	D-serine	Dser	L-N-methyl-t-butylglycine	Nmtbug

- 30 -

	D-threonine	Dthr	L-norleucine	Nle
	D-tryptophan	Dtrp	L-norvaline	Nva
	D-tyrosine	Dtyr	α -methyl-aminoisobutyrate	Maib
	D-valine	Dval	α -methyl- γ -aminobutyrate	Mgabu
5	D- α -methylalanine	Dmala	α -methylcyclohexylalanine	Mchexa
	D- α -methylarginine	Dmarg	α -methylcyclopentylalanine	Mcpen
	D- α -methylasparagine	Dmasn	α -methyl- α -naphthylalanine	Manap
	D- α -methylaspartate	Dmasp	α -methylpenicillamine	Mpen
	D- α -methylcysteine	Dmcys	N-(4-aminobutyl)glycine	Nglu
10	D- α -methylglutamine	Dmgln	N-(2-aminoethyl)glycine	Naeg
	D- α -methylhistidine	Dmhis	N-(3-aminopropyl)glycine	Norn
	D- α -methylisoleucine	Dmile	N-amino- α -methylbutyrate	Nmaabu
	D- α -methylleucine	Dmleu	α -naphthylalanine	Anap
	D- α -methyllysine	Dmlys	N-benzylglycine	Nphe
15	D- α -methylmethionine	Dmmet	N-(2-carbamylethyl)glycine	Ngln
	D- α -methylornithine	Dmorn	N-(carbamylmethyl)glycine	Nasn
	D- α -methylphenylalanine	Dmphe	N-(2-carboxyethyl)glycine	Nglu
	D- α -methylproline	Dmpro	N-(carboxymethyl)glycine	Nasp
	D- α -methylserine	Dmser	N-cyclobutylglycine	Ncbut
20	D- α -methylthreonine	Dmthr	N-cycloheptylglycine	Nchep
	D- α -methyltryptophan	Dmtrp	N-cyclohexylglycine	Nchex
	D- α -methyltyrosine	Dmty	N-cyclodecylglycine	Ncdec
	D- α -methylvaline	Dmval	N-cylcododecylglycine	Ncdod
	D-N-methylalanine	Dnmala	N-cyclooctylglycine	Ncoct
25	D-N-methylarginine	Dnmarg	N-cyclopropylglycine	Ncpro
	D-N-methylasparagine	Dnmasn	N-cycloundecylglycine	Ncund
	D-N-methylaspartate	Dnmasp	N-(2,2-diphenylethyl)glycine	Nbhm
	D-N-methylcysteine	Dnmcys	N-(3,3-diphenylpropyl)glycine	Nbhe
	D-N-methylglutamine	Dnmgln	N-(3-guanidinopropyl)glycine	Narg
30	D-N-methylglutamate	Dnmglu	N-(1-hydroxyethyl)glycine	Nthr

- 31 -

	D-N-methylhistidine	Dnmhis	N-(hydroxyethyl)glycine	Nser
	D-N-methylisoleucine	Dnmile	N-(imidazolylethyl)glycine	Nhis
	D-N-methylleucine	Dnmleu	N-(3-indolylyethyl)glycine	Nhtrp
	D-N-methyllysine	Dnmlys	N-methyl- γ -aminobutyrate	Nmgabu
5	N-methylcyclohexylalanine	Nmchexa	D-N-methylmethionine	Dnmmt
	D-N-methylornithine	Dnmorn	N-methylcyclopentylalanine	Nmcpen
	N-methylglycine	Nala	D-N-methylphenylalanine	Dnmphe
	N-methylaminoisobutyrate	Nmaib	D-N-methylproline	Dnmpro
	N-(1-methylpropyl)glycine	Nile	D-N-methylserine	Dnmser
10	N-(2-methylpropyl)glycine	Nleu	D-N-methylthreonine	Dnmthr
	D-N-methyltryptophan	Dnmtrp	N-(1-methylethyl)glycine	Nval
	D-N-methyltyrosine	Dnmtyr	N-methyl- <i>n</i> -naphthylalanine	Nmanap
	D-N-methylvaline	Dnmval	N-methylpenicillamine	Nmpen
	γ -aminobutyric acid	Gabu	N-(<i>p</i> -hydroxyphenyl)glycine	Nhtyr
15	L- <i>t</i> -butylglycine	Tbug	N-(thiomethyl)glycine	Ncys
	L-ethylglycine	Etg	penicillamine	Pen
	L-homophenylalanine	Hphe	L- α -methylalanine	Mala
	L- α -methylarginine	Marg	L- α -methylasparagine	Masn
	L- α -methylaspartate	Masp	L- α -methyl- <i>t</i> -butylglycine	Mtbug
20	L- α -methylcysteine	Mcys	L-methylethylglycine	Metg
	L- α -methylglutamine	Mgln	L- α -methylglutamate	Mglu
	L- α -methylhistidine	Mhis	L- α -methylhomophenylalanine	Mhphe
	L- α -methylisoleucine	Mile	N-(2-methylthioethyl)glycine	Nmet
	L- α -methylleucine	Mleu	L- α -methyllysine	Mlys
25	L- α -methylmethionine	Mmet	L- α -methylnorleucine	Mnle
	L- α -methylnorvaline	Mnva	L- α -methylornithine	Morn
	L- α -methylphenylalanine	Mphe	L- α -methylproline	Mpro
	L- α -methylserine	Mser	L- α -methylthreonine	Mthr
	L- α -methyltryptophan	Mtrp	L- α -methyltyrosine	Mtyr
30	L- α -methylvaline	Mval	L-N-methylhomophenylalanine	Nmhphe

- 32 -

N-(N-(2,2-diphenylethyl)	Nnbhm	N-(N-(3,3-diphenylpropyl)	Nnbhe
carbamylmethyl)glycine		carbamylmethyl)glycine	
1-carboxy-1-(2,2-diphenyl-	Nmbc		
ethylamino)cyclopropane			

5

Crosslinkers can be used, for example, to stabilize 3D conformations, using homo-bifunctional crosslinkers such as the bifunctional imido esters having (CH₂)_n spacer groups with n=1 to n=6, glutaraldehyde, N-hydroxysuccinimide esters and hetero-bifunctional

10 reagents which usually contain an amino-reactive moiety such as N-hydroxysuccinimide and another group specific-reactive moiety such as maleimido or dithio moiety (SH) or carbodiimide (COOH). In addition, peptides can be conformationally constrained by, for example, incorporation of C_α and N_α-methylamino acids, introduction of double bonds between C_α and C_β atoms of amino acids and the formation of cyclic peptides or analogs

15 by introducing covalent bonds such as forming an amide bond between the N and C termini, between two side chains or between a side chain and the N or C terminus.

All such modifications may also be useful in stabilizing the AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 molecule for use in *in vivo*

20 administration protocols or for diagnostic purposes.

As stated above, the expression product may be a RNA or protein.

The term "protein" should be understood to encompass peptides, polypeptides and

25 proteins. The protein may be glycosylated or unglycosylated and/or may contain a range of other molecules fused, linked, bound or otherwise associated to the protein such as amino acids, lipids, carbohydrates or other peptides, polypeptides or proteins. Reference hereinafter to a "protein" includes a protein comprising a sequence of amino acids as well as a protein associated with other molecules such as amino acids, lipids, carbohydrates or

30 other peptides, polypeptides or proteins.

- 33 -

In a particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:1 or a derivative, homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:1 or a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or its complementary form under low stringency conditions.

In another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:2 or a derivative, homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:2 or a nucleotide sequence capable of hybridizing to SEQ ID NO:2 or its complementary form under low stringency conditions.

In still another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:3 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:3 or a nucleotide sequence capable of hybridizing to SEQ ID NO:3 or their complementary form under low stringency conditions.

In yet another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:5 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:5 or a nucleotide sequence capable of hybridizing to SEQ ID NO:5 or its complementary form under low stringency conditions.

In another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:6 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:6 or a nucleotide sequence capable of hybridizing to SEQ ID NO:6 or its complementary form under low stringency conditions.

- 34 -

In a further particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:7 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:7 or a nucleotide sequence capable of hybridizing to SEQ ID NO:7 or its
5 complementary form under low stringency conditions.

In still another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:8 or a derivative homolog or analog thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID
10 NO:8 or a nucleotide sequence capable of hybridizing to SEQ ID NO:8 or its complementary form under low stringency conditions.

In yet another particularly preferred embodiment, the expression product is encoded by a sequence of nucleotides comprising SEQ ID NO:9 or a derivative homolog or analog
15 thereof including a nucleotide sequence having at least about 30% similarity to SEQ ID NO:9 or a nucleotide sequence capable of hybridizing to SEQ ID NO:9 or its complementary form under low stringency conditions.

Higher similarities are also contemplated by the present invention such as greater than 40%
20 or 50% or 60% or 70% or 80% or 90% or 95% or 96% or 97% or 98% or 99% or above.

Another aspect of the present invention is directed to an isolated expression product selected from the list consisting of:-

- 25 (i) an mRNA or protein encoded by a novel nucleic acid molecule which molecule is differentially expressed in one or more of stomach, liver or hypothalamus tissue from *Psammomys obesus* animals under fed or fasting conditions or animals which are diabetic or non-diabetic or a derivative, homolog, analog, chemical equivalent or mimetic thereof;

30

- 35 -

- 5 (ii) an mRNA or protein encoded by a novel nucleic acid molecule which molecule is differentially expressed in one or more of stomach, liver or hypothalamus tissue from *Psammomys obesus* animals under fed or fasting conditions or animals which are diabetic or non-diabetic or a derivative, homolog, analog, chemical equivalent or mimetic thereof;
- 10 (iii) AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 or AGT-504 or a derivative, homolog, analog, chemical equivalent or mimetic thereof;
- 10 (iv) a protein encoded by a nucleotide sequence comprising SEQ ID NO:1 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 15 (vi) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:2 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 20 (vii) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:3 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to these sequences or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 25 (viii) a protein comprising an amino acid sequence substantially as set forth in SEQ ID NO:4 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to these sequences or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- 30 (ix) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:5 or a derivative, homolog or analog thereof or a sequence encoding an amino acid

- 36 -

sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;

(x) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:6
5 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;

(xi) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:7
10 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;

(xii) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:8
15 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;

(xiii) a protein encoded by a nucleotide sequence substantially comprising SEQ ID NO:9
20 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;

(xiv) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide
25 sequence comprising SEQ ID NO:1 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions;

(xv) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide
30 sequence comprising SEQ ID NO:2 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions;

- 37 -

- (xvi) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide sequence comprising SEQ ID NO:3 or their complementary forms or a derivative, homolog or analog thereof under low stringency conditions;
- 5 (xvii) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide sequence comprising SEQ ID NO:5 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions;
- (xviii) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide
10 sequence comprising SEQ ID NO:6 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions;
- (xix) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide
15 sequence comprising SEQ ID NO:7 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions;
- (xx) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide
20 sequence comprising SEQ ID NO:8 or its complementary form or a derivative, homolog or analog thereof under low stringency conditions; and
- (xxi) a protein encoded by a nucleic acid molecule capable of hybridizing to a nucleotide
sequence comprising SEQ ID NO:9 or its complementary form or a derivative,
homolog or analog thereof under low stringency conditions.
- 25 An example of an expression product is the amino acid sequence set forth in SEQ ID NO:4 (AGT-121).

The protein of the present invention is preferably in isolated form. By "isolated" is meant a
protein having undergone at least one purification step and this is conveniently defined, for
30 example, by a composition comprising at least about 10% subject protein, preferably at
least about 20%, more preferably at least about 30%, still more preferably at least about

- 38 -

40-50%, even still more preferably at least about 60-70%, yet even still more preferably 80-90% or greater of subject protein relative to other components as determined by molecular weight, amino acid sequence or other convenient means. The protein of the present invention may also be considered, in a preferred embodiment, to be biologically
5 pure.

Without limiting the theory or mode of action of the present invention, the expression of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and/or AGT-504 is thought to relate to regulation of body weight and glucose homeostasis. Modulation of
10 expression of these genes is thought *inter alia* to regulate energy balance *via* effects on energy intake and also effects on carbohydrate/fat metabolism. The energy intake effects are likely to be mediated *via* the central nervous system but peripheral effects on the metabolism of both carbohydrate and fat are possible. The expression of these genes may also be regulated by fasting and feeding. Accordingly, regulating the expression and/or
15 activity of these genes or their expression products provides a mechanism for regulating both body weight and energy metabolism, including carbohydrate and fat metabolism.

The identification of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* permits the generation of a range of therapeutic molecules capable of modulating
20 expression of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* or modulating the activity of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504*. Modulators contemplated by the present invention include agonists and antagonists of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* expression. Antagonists of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123*
25 and *AGT-504* expression include antisense molecules, ribozymes and co-suppression molecules (including any molecules which induce RNAi). Agonists include molecules which increase promoter activity or which interfere with negative regulatory mechanisms. Antagonists of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* include antibodies and inhibitor peptide fragments. All such molecules may first need
30 to be modified to enable such molecules to penetrate cell membranes. Alternatively, viral agents may be employed to introduce genetic elements to modulate expression of *AGT-*

119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504. In so far as AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 act in association with other genes such as the *ob* gene which encodes leptin, the therapeutic molecules may target *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and *AGT-504* and *ob* genes or their translation products.

The present invention contemplates, therefore, a method for modulating expression of *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and *AGT-504* in a mammal, said method comprising contacting the *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and *AGT-504* gene with an effective amount of a modulator of *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and *AGT-504* expression for a time and under conditions sufficient to up-regulate or down-regulate or otherwise modulate expression of *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and *AGT-504*.

For example, a nucleic acid molecule encoding *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and *AGT-504* or a derivative or homolog thereof may be introduced into a cell to enhance the ability of that cell to produce *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and *AGT-504*, conversely, *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and *AGT-504* sense and/or antisense sequences such as oligonucleotides may be introduced to decrease expression of the genes at the level of transcription, post-transcription or translation. Sense sequences preferably encode hair pin RNA molecules or double-stranded RNA molecules.

Another aspect of the present invention contemplates a method of modulating activity of *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and *AGT-504* in a mammal, said method comprising administering to said mammal a modulating effective amount of a molecule for a time and under conditions sufficient to increase or decrease *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and *AGT-504* activity. The molecule may be a proteinaceous molecule or a chemical entity and may also be a derivative of *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and *AGT-504* or its ligand.

- 40 -

Modulating levels of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* expression or *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504* activity or function is important in the treatment of a range of conditions
5 such as obesity, anorexia, energy imbalance, diabetes, metabolic syndrome, dyslipidemia, hypertension and insulin resistance. It may also be useful in the agricultural industry to assist in the generation of leaner animals, or where required, more obese animals. Accordingly, mammals contemplated by the present invention include but are not limited to humans, primates, livestock animals (e.g. pigs, sheep, cows, horses, donkeys),
10 laboratory test animals (e.g. mice, rats, guinea pigs, hamsters, rabbits), companion animals (e.g. dogs, cats) and captured wild animals (e.g. foxes, kangaroos, deer). A particularly preferred host is a human, primate or livestock animal.

Accordingly, the present invention contemplates therapeutic and prophylactic use of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504* expression
15 products or *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* genetic mutants and/or agonists or antagonists agents thereof.

The present invention contemplates, therefore, a method of modulating expression of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504* in a mammal,
20 said method comprising contacting the *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504* genes with an effective amount of an agent for a time and under conditions sufficient to up-regulate, down-regulate or otherwise modulate expression of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504*.

25

Another aspect of the present invention contemplates a method of modulating activity of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504* in a subject, said method comprising administering to said subject a modulating effective amount of an agent for a time and under conditions sufficient to increase or decrease *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504* activity or
30 function.

- 41 -

Modulation of activity by the administration of an agent to a mammal can be achieved by one of several techniques, including, but in no way limited to, introducing into a mammal a proteinaceous or non-proteinaceous molecule which:

5

(i) modulates expression of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504*;

10

(ii) functions as an antagonist of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504*; and/or

(iii) functions as an agonist of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504*.

15 The molecules which may be administered to a mammal in accordance with the present invention may also be linked to a targeting means such as a monoclonal antibody, which provides specific delivery of these molecules to the target cells.

20 A further aspect of the present invention relates to the use of the invention in relation to mammalian disease conditions. For example, the present invention is particularly useful in a therapeutic or prophylactic treatment of obesity, anorexia, diabetes or energy imbalance.

25 Accordingly, another aspect of the present invention relates to a method of treating a mammal suffering from a condition characterized by one or more symptoms of obesity, anorexia, diabetes and/or energy imbalance, said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504* or sufficient to modulate the activity of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504*.

30

- 42 -

In another aspect, the present invention relates to a method of treating a mammal suffering from a disease condition characterized by one or more symptoms of obesity, anorexia, diabetes or energy imbalance, said method comprising administering to said mammal an effective amount of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123
5 and/or AGT-504 or *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and/or *AGT-504*.

An agent includes proteinaceous or non-proteinaceous molecules such as antibodies, natural products, chemical entities or nucleic acid molecules (including antisense
10 molecules, sense molecules, ribozymes, ds-RNA molecules or DNA-targeting molecules).

An "effective amount" means an amount necessary at least partly to attain the desired immune response (e.g. against AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 or AGT-504) or to delay the onset or inhibit progression or halt altogether the
15 onset or progression of a particular condition.

In accordance with these methods, AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and/or AGT-504 or *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and/or *AGT-504* or agents capable of modulating the expression or activity of said
20 molecules may be co-administered with one or more other compounds or other molecules. By "co-administered" is meant simultaneous administration in the same formulation or in two different formulations *via* the same or different routes or sequential administration by the same or different routes. By "sequential" administration is meant a time difference of from seconds, minutes, hours or days between the administration of the two types of
25 molecules. These molecules may be administered in any order.

In yet another aspect, the present invention relates to the use of an agent capable of modulating the expression of *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123* and/or *AGT-504* or a derivative, homolog or analog thereof in the manufacture of a
30 medicament for the treatment of a condition characterized by obesity, anorexia, weight maintenance, diabetes and/or energy imbalance.

In still yet another aspect, the present invention relates to the use of an agent capable of modulating the activity of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and/or AGT-504 or a derivative, homolog, analog, chemical equivalent or mimetic thereof
5 in the manufacture of a medicament for the treatment of a condition characterized by obesity, anorexia, weight maintenance, diabetes and/or energy imbalance.

A further aspect of the present invention relates to the use of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504* or derivative, homolog or analog
10 thereof or AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and/or AGT-504 or derivative, homolog, analog, chemical equivalent or mimetic thereof in the manufacture of a medicament for the treatment of a condition characterized by obesity, anorexia, weight maintenance, diabetes and/or energy imbalance.

15 Still yet another aspect of the present invention relates to agents for use in modulating the expression of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504* or a derivative, homolog or analog thereof.

A further aspect relates to agents for use in modulating AGT-119, AGT-120, AGT-121,
20 AGT-122, AGT-422, AGT-123 and/or AGT-504 activity or a derivative, homolog, analog, chemical equivalent or mimetic thereof.

Still another aspect of the present invention relates to *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and/or *AGT-504* or derivative, homolog or analog thereof or
25 AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and/or AGT-504 or derivative, homolog, analog, chemical equivalent or mimetic thereof for use in treating a condition characterized by one or more symptoms of obesity, anorexia, weight maintenance, diabetes and/or energy imbalance.

30 In a related aspect of the present invention, the mammal undergoing treatment may be a human or an animal in need of therapeutic or prophylactic treatment.

- 44 -

Accordingly, the present invention contemplates in one embodiment a composition comprising a modulator of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* expression or *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* activity and one or more pharmaceutically acceptable carriers and/or diluents. In another embodiment, the composition comprises *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* or a derivative, homolog, analog or mimetic thereof and one or more pharmaceutically acceptable carriers and/or diluents. The compositions may also comprise leptin or modulations of leptin activity or *ob* expression.

10

For brevity, all such components of such a composition are referred to as "active components".

The compositions of active components in a form suitable for injectable use include sterile aqueous solutions (where water soluble) and sterile powders for the extemporaneous preparation of sterile injectable solutions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.

20

The carrier can be a solvent or other medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.

The preventions of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

30

- 45 -

Sterile injectable solutions are prepared by incorporating the active components in the required amount in the appropriate solvent with optionally other ingredients, as required, followed by sterilization by, for example, filter sterilization, irradiation or other convenient means. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze-drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.

When *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* or *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* are suitably protected, they may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsule, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, the active compound may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 5 to about 80% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 0.1 μg and 2000 mg of active compound.

The tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such a sucrose, lactose or saccharin may be added or a flavouring agent such as peppermint, oil of wintergreen, or cherry flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be

- 46 -

present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavouring such as cherry or orange flavour. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and formulations.

Pharmaceutically acceptable carriers and/or diluents include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, use thereof in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the mammalian subjects to be treated; each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the novel dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active material for the treatment of disease in living subjects having a diseased condition in which bodily health is impaired as herein disclosed in detail.

The principal active component may be compounded for convenient and effective administration in sufficient amounts with a suitable pharmaceutically acceptable carrier in dosage unit form. A unit dosage form can, for example, contain the principal active component in amounts ranging from 0.5 μg to about 2000 mg. Expressed in proportions,

- 47 -

the active compound is generally present in from about 0.5 µg to about 2000 mg/ml of carrier. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the said ingredients.

5

In general terms, effective amounts of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* or *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* will range from 0.01 ng/kg/body weight to above 10,000 mg/kg/body weight. Alternative amounts range from 0.1 ng/kg/body weight to above 1000 mg/kg/body weight. The active ingredients may be administered per minute, hour, day, week, month or year depending on the condition being treated. The route of administration may vary and includes intravenous, intraperitoneal, sub-cutaneous, intramuscular, intranasal, *via* suppository, *via* infusion, *via* drip, orally or *via* other convenient means.

15 The pharmaceutical composition may also comprise genetic molecules such as a vector capable of transfecting target cells where the vector carries a nucleic acid molecule capable of modulating *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* expression or *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* activity. The vector may, for example, be a viral vector.

20

Still another aspect of the present invention is directed to antibodies to *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* and their derivatives and homologs insofar as *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* are proteins. Such antibodies may be monoclonal or polyclonal and may be selected from naturally occurring antibodies to *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* or may be specifically raised to *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* or derivatives or homologs thereof. In the case of the latter, *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* or their derivatives or homologs may first need to be associated with a carrier molecule. The antibodies and/or recombinant *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* or their derivatives of the present

30

- 48 -

invention are particularly useful as therapeutic or diagnostic agents. An antibody "to" a molecule includes an antibody specific for said molecule.

AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 and their
5 derivatives can be used to screen for naturally occurring antibodies to AGT-119, AGT-
120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 which may occur in certain
autoimmune diseases. Alternatively, specific antibodies can be used to screen for AGT-
119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504. Techniques for
such assays are well known in the art and include, for example, sandwich assays and
10 ELISA.

Antibodies to AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-
504 of the present invention may be monoclonal or polyclonal and may be selected from
naturally occurring antibodies to the AGT-119, AGT-120, AGT-121, AGT-122, AGT-422,
15 AGT-123 and AGT-504 or may be specifically raised to the AGT-119, AGT-120 and
AGT-121 or their derivatives. In the case of the latter, the AGT-119, AGT-120, AGT-121,
AGT-122, AGT-422, AGT-123 and AGT-504 protein may need first to be associated with
a carrier molecule. Alternatively, fragments of antibodies may be used such as Fab
fragments. Furthermore, the present invention extends to recombinant and synthetic
20 antibodies and to antibody hybrids. A "synthetic antibody" is considered herein to include
fragments and hybrids of antibodies. The antibodies of this aspect of the present invention
are particularly useful for immunotherapy and may also be used as a diagnostic tool or as a
means for purifying AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and
AGT-504.

25

For example, specific antibodies can be used to screen for AGT-119, AGT-120, AGT-121,
AGT-122, AGT-422, AGT-123 and AGT-504 proteins. The latter would be important, for
example, as a means for screening for levels of AGT-119, AGT-120, AGT-121, AGT-122,
AGT-422, AGT-123 and AGT-504 in a cell extract or other biological fluid or purifying
30 AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 made by

- 49 -

recombinant means from culture supernatant fluid. Techniques for the assays contemplated herein are known in the art and include, for example, sandwich assays and ELISA.

It is within the scope of this invention to include any second antibodies (monoclonal, polyclonal or fragments of antibodies) directed to the first mentioned antibodies discussed
5 above. Both the first and second antibodies may be used in detection assays or a first antibody may be used with a commercially available anti-immunoglobulin antibody. An antibody as contemplated herein includes any antibody specific to any region of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504.

10

Both polyclonal and monoclonal antibodies are obtainable by immunization with the enzyme or protein and either type is utilizable for immunoassays. The methods of obtaining both types of sera are well known in the art. Polyclonal sera are less preferred but are relatively easily prepared by injection of a suitable laboratory animal with an
15 effective amount of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504, or antigenic parts thereof, collecting serum from the animal, and isolating specific sera by any of the known immunoabsorbent techniques. Although antibodies produced by this method are utilizable in virtually any type of immunoassay, they are generally less favoured because of the potential heterogeneity of the product.

20

The use of monoclonal antibodies in an immunoassay is particularly preferred because of the ability to produce them in large quantities and the homogeneity of the product. The preparation of hybridoma cell lines for monoclonal antibody production derived by fusing an immortal cell line and lymphocytes sensitized against the immunogenic preparation can
25 be done by techniques which are well known to those who are skilled in the art. (See, for example, Douillard and Hoffman, Basic Facts about Hybridomas, in *Compendium of Immunology* Vol. II, ed. by Schwartz, 1981; Kohler and Milstein, *Nature* 256: 495-499, 1975; Kohler and Milstein, *European Journal of Immunology* 6: 511-519, 1976.)

30 Another aspect of the present invention contemplates a method for detecting AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 or a derivative or

- 50 -

homolog thereof in a biological sample from a subject, said method comprising contacting said biological sample with an antibody specific for AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 or their antigenic derivatives or homologs for a time and under conditions sufficient for a complex to form, and then detecting said
5 complex.

The presence of the complex is indicative of the presence of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504. This assay may be quantitated or semi-quantitated to determine a propensity to develop obesity or other conditions or to
10 monitor a therapeutic regimen.

The presence of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 may be accomplished in a number of ways such as by Western blotting and ELISA procedures. A wide range of immunoassay techniques are available as can be seen
15 by reference to U.S. Patent Nos. 4,016,043, 4,424,279 and 4,018,653. These, of course, include both single-site and two-site or "sandwich" assays of the non-competitive types, as well as in the traditional competitive binding assays. These assays also include direct binding of a labelled antibody to a target.

20 Sandwich assays are among the most useful and commonly used assays. A number of variations of the sandwich assay technique exist, and all are intended to be encompassed by the present invention. Briefly, in a typical forward assay, an unlabelled antibody is immobilized on a solid substrate and the sample to be tested brought into contact with the bound molecule. After a suitable period of incubation, for a period of time sufficient to
25 allow formation of an antibody-AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 complex, a second antibody specific to the AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504, labelled with a reporter molecule capable of producing a detectable signal, is then added and incubated, allowing time sufficient for the formation of another complex of antibody-AGT-119, AGT-120,
30 AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504-labelled antibody. Any unreacted material is washed away, and the presence of AGT-119, AGT-120, AGT-121, AGT-122,

- 51 -

AGT-422, AGT-123 and AGT-504 is determined by observation of a signal produced by the reporter molecule. The results may either be qualitative, by simple observation of the visible signal, or may be quantitated by comparing with a control sample containing known amounts of hapten. Variations on the forward assay include a simultaneous assay, 5 in which both sample and labelled antibody are added simultaneously to the bound antibody. These techniques are well known to those skilled in the art, including any minor variations as will be readily apparent. In accordance with the present invention, the sample is one which might contain AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504 including cell extract, tissue biopsy or possibly serum, saliva, mucosal 10 secretions, lymph, tissue fluid and respiratory fluid. The sample is, therefore, generally a biological sample comprising biological fluid but also extends to fermentation fluid and supernatant fluid such as from a cell culture.

The solid surface is typically glass or a polymer, the most commonly used polymers being 15 cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene. The solid supports may be in the form of tubes, beads, discs or microplates, or any other surface suitable for conducting an immunoassay. The binding processes are well-known in the art and generally consist of cross-linking covalently binding or physically adsorbing, the polymer-antibody complex to the solid surface which is then washed in preparation for 20 the test sample. An aliquot of the sample to be tested is then added to the solid phase complex and incubated for a period of time sufficient (e.g. 2-40 minutes or overnight if more convenient) and under suitable conditions (e.g. from room temperature to about 37°C) to allow binding of any subunit present in the antibody. Following the incubation period, the antibody subunit solid phase is washed and dried and incubated with a second 25 antibody specific for a portion of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504. The second antibody is linked to a reporter molecule which is used to indicate the binding of the second antibody to AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-123 and AGT-504.

30 An alternative method involves immobilizing the target molecules in the biological sample and then exposing the immobilized target to specific antibody which may or may not be

- 52 -

labelled with a reporter molecule. Depending on the amount of target and the strength of the reporter molecule signal, a bound target may be detectable by direct labelling with the antibody. Alternatively, a second labelled antibody, specific to the first antibody is exposed to the target-first antibody complex to form a target-first antibody-second antibody tertiary
5 complex. The complex is detected by the signal emitted by the reporter molecule.

By "reporter molecule" as used in the present specification, is meant a molecule which, by its chemical nature, provides an analytically identifiable signal which allows the detection of antigen-bound antibody. Detection may be either qualitative or quantitative. The most
10 commonly used reporter molecules in this type of assay are either enzymes, fluorophores or radionuclide containing molecules (i.e. radioisotopes) and chemiluminescent molecules.

In the case of an enzyme immunoassay, an enzyme is conjugated to the second antibody, generally by means of glutaraldehyde or periodate. As will be readily recognized, however,
15 a wide variety of different conjugation techniques exist, which are readily available to the skilled artisan. Commonly used enzymes include horseradish peroxidase, glucose oxidase, β -galactosidase and alkaline phosphatase, amongst others. The substrates to be used with the specific enzymes are generally chosen for the production, upon hydrolysis by the corresponding enzyme, of a detectable colour change. Examples of suitable enzymes
20 include alkaline phosphatase and peroxidase. It is also possible to employ fluorogenic substrates, which yield a fluorescent product rather than the chromogenic substrates noted above. In all cases, the enzyme-labelled antibody is added to the first antibody hapten complex, allowed to bind, and then the excess reagent is washed away. A solution containing the appropriate substrate is then added to the complex of antibody-antigen-
25 antibody. The substrate will react with the enzyme linked to the second antibody, giving a qualitative visual signal, which may be further quantitated, usually spectrophotometrically, to give an indication of the amount of hapten which was present in the sample. A "reporter molecule" also extends to use of cell agglutination or inhibition of agglutination such as red blood cells on latex beads, and the like.

30

- 53 -

Alternately, fluorescent compounds, such as fluorescein and rhodamine, may be chemically coupled to antibodies without altering their binding capacity. When activated by illumination with light of a particular wavelength, the fluorochrome-labelled antibody absorbs the light energy, inducing a state of excitability in the molecule, followed by
5 emission of the light at a characteristic colour visually detectable with a light microscope. As in the EIA, the fluorescent-labelled antibody is allowed to bind to the first antibody-hapten complex. After washing off the unbound reagent, the remaining tertiary complex is then exposed to the light of the appropriate wavelength. The fluorescence observed indicates the presence of the hapten of interest. Immunofluorescence and EIA techniques
10 are both very well established in the art and are particularly preferred for the present method. However, other reporter molecules, such as radioisotope, chemiluminescent or bioluminescent molecules, may also be employed.

The present invention also contemplates genetic assays such as involving, for example,
15 PCR analysis to detect *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-123* and *AGT-504* or their derivatives.

Real-time PCR is also particularly useful for assaying for particular genetic molecules.

20 The present invention is further described by the following non-limiting Examples.

- 54 -

EXAMPLE 1

Psammomys obesus

In the following examples, *Psammomys obesus* rats were used for differential expression studies under different conditions. The rats are divided into three groups, based on metabolic phenotype, as follows:-

Group A animals : lean
Group B animals : obese, non-diabetic
10 Group C animals : obese, diabetic.

EXAMPLE 2

Partial sequence of Psammomys obesus AGT-119

15 AGT-119 was identified using differential display PCR of stomach cDNA from fed, fasted and re-fed *Psammomys obesus*.

The partial nucleotide sequence is as follows:-

20 AATGAAAGAATTGATTGATACGCAACCAAATTAGCCAGTGAGGTTAGNNNCNGGATTATCG
TGACCAGATAGGAGCCTTGGAAAATGACTAAGAAAAATGAAAAACAGCCTAAAATGTCATT
AGCCCAACAAGATGCGTTAAAACGCCTGGATCAAGTTAGAANGCAGAAAAGCGAAAGCC
[SEQ ID NO:1].

25

EXAMPLE 3

AGT-119 gene expression

Real-time PCR analysis of AGT-119 found dramatically lower levels of expression in fasted and re-fed animals when compared to fed animals (Figure 1). In most fasted and re-fed animals the levels of AGT-119 were undetectable. Fasting was for 16 hours, fed animals had *ad libitum* access to lab chow and re-fed animals were fasted for 16 hours then allowed *ad libitum* access to lab chow for 1 hour. These results were confirmed with two sets of primers targeting the gene of interest.

- 55 -

EXAMPLE 4***AGT-119 sequence homology***

- 5 The AGT-119 sequence does not show significant homology with anything on the public database (BLASTN version 2.2.1).

EXAMPLE 5***Partial sequence of *Psammomys obesus* AGT-120***

10

AGT-120 was identified using differential display PCR of stomach cDNA from fed, fasted and re-fed *Psammomys obesus*.

The partial nucleotide sequence is as follows:-

15

GCTGATGGCGATGAATGAACACTGCGTTTGGCTGGCCTTATCAATTCCCGCTTTTTCTTGGA
 TGAAAAAGACTAACCATGATCGGGCCCAACGGCGGAAGTCGCTTTTGTACCAGTAGTGAT
 GGTGCCGGGATCAAGTGCCACGATTGAGCGTTTCAATTCAGTATTGCGATGCTTAATAAA
 GATTCGCCGCACCCTCACAGTGTGTTAAAGATTAAGTCATGAAAGATGGCAGTTTAAA
 20 ATACAAGGGCAGCATTAAATCGCGGTGATAATGAACCCTTTATTGTGATTGGTTTTGAAA
 ATAATAAAGATGGCTATAGTAATATTAAGAAGCAAGCAAGCTGGCTAGATATTGCCTTTTA
 TGAGATCTCGCNAACTTATAAAATTTAAACAACCTTTAAGGCCCTTTGGCCATTCAAATGGAG
 GGCTGGTGTGGACATATTGGTTAGAGCATTATTATTTCAGAGTATGAGTCAGAAATCA
 AAATCAAGCGTTGATGACTTTGGCTTACCATTAACTTTGACGAAGACAATCTGAAT
 25 CACCGGACCCAGATGCTGGCTGACTTTATTAATATCGGAAACGACTTCCAAAAACGCTC
 AAAGTTTATTTCACTGACTGGTGGCCAGACCTATGAATCTGACGGGATTGTTCTGAAAA
 TAGTGTAGCCGCAGCCAAGTATATTTTCCAAAATCAAGTGAAGAGCTTTATGGAAAT
 TACGGTTACGGGTAAGCAGCTAATCACTCAGATTTACCGCAAAATGAACAAGTAGTGCTA
 30 GTGATGAATCCACCACTCACTAAAGATAATAAAAAAAAAAAAA [SEQ ID NO:2].

EXAMPLE 6***AGT-120 gene expression***

- 35 AGT-120 expression was significantly higher in the fed group (n=8) compared to fasted (n=12) and re-fed animals (n=8). There was no difference between fasted and re-fed

animals (Figure 2). No significant correlations were found between AGT-120 expression and stomach weight, stomach content, glucose or insulin levels.

EXAMPLE 7

5 *AGT-120 gene homology*

The AGT-120 sequence shows homology to a *Lactobacillus gasseri* hypothetical protein (NZ_AAAB01000011). A human homolog is yet to be identified.

10 EXAMPLE 8

Sequence of Psammomys obesus AGT-121

AGT-121 was identified using differential display PCR of hypothalamic cDNA from diabetic and non-diabetic *Psammomys obesus*.

15 AGT-121 is a hypothalamic gene that was initially identified by differential display. From primary gene expression data in fed/fasted hypothalamus, it was of interest because of the large increase in its expression in Group B and C animals, as well as the large disparity in signal between the animals.

20 The nucleotide sequence is as follows:-

25 CAGACTCCTTGGAATAAAGGAATGCAATTCTGCCACCATGATGGAAGGACTGAAAAACGT
 ACAAGGAAGGCCTTTGGAATACGGAAGAAAGAAAAAGACACTGACTCTACAGGCTCACCAGA
 TCGAGATGGAATGCAGCCAGCCACACGAGCTCCCCTACCATAGCAAAGCAGAGTGTGCC
 GAGAAGGAGGGAACAAAGCTTCGAAGAAAAGCAATGGGGCACCAAATGGATTTTATGCGGAA
 ATTGATTGGGAAAGATATAACTCACCTGAGCTGGATGAAGAAGGTTACAGCATCAGACCTGA
 GGAACCAGGCTCTACCAAAGGAAAGCACTTTTATTCTTCAAGTGAATCCGAAGAGGAGGAAG
 AATCGCACAAAGAGTTCAATATCAAGATTA AACCTTGCAGTCCAAGGACATCCTTAAGAAT
 30 GCTGCAACAGTAGACGAGCTGAAGGCTTCCATAGGCAACATTGCACCTTCCCTTCGCCTGT
 GAGGAAAAGTCCGAGGCGCAGCCCGGGTGCAATTTAAAGGAACCTTATCCAGTGAAGAAGTCG
 CAAGACCCAGGCGTTCACCCCAACTCCAGA ACTTACAAGCAAGAAGCCTCTGGACGACACT
 CTGGCCCTTGCTCCCCTCTTTGGCCACCGGTTAGAATCTGCTTTTGATGGACACAAGACGGA
 AGTTCTTTTAGATCAGCTGAGATATGGGGTT CAGGCCAACAGTTAACCCAAGCATGGAGT
 35 CACCAAAGCTAGCAAGACCTTTTCCCACTGGAACCCCTCCACCTCTGCCTCCAAAACTGTA
 CCAGCCACCCCGCTCGGACAGGCTCCCCCTTAACAGTGGCGACAGGAAATGACCAGGCAGC
 CACAGAGGCCAAAAATTGAGAACTACCATCCATCAGTGACCTGGACAGCATTTTTGGCCCCG
 TGTGTCCCCCAAGTCTGTTGCTGTTAATACTGAGGAGACGTGGGTCCATTTCTCTGATGCA
 TCCCCGAAACATGTTACTCCAGAGTTGACTCCAAGGGAAAAGGTGGTGACCCACCAGCTGC

ATCAGACATCCCAGCTGACTCCCCAACTCCAGGCCCGCCTGGCCCCCAGGCTCGGCAGGTC
 CCCCAGGGCCTCCTGGTCCTCGCAATGTACCATCTCCGCTCAATTTAGAAGAAGTCCAGAAG
 AAAGTCGCTGAGCAGACCTTCATTAAGATGATTACTTAGAAACACTCTCATCTCCTAAAAGA
 GTGTGGGTTGGGACAGAGCAACTCCACCTCCCCACCACCACCACCTACAGGACTGTGG
 5 TTTTCGTCCTCCCGGACCTGGCTCGGGCAGTGGTACGGGGACCGCCAGTGGTGCATCGTCCCT
 GCTCGGCCAGCCACCCCTTAGTTCTTGCAGCTGCTCCACTCCGCTCCACCTCCTCCCCG
 GCCTCCATCCCGGCCAAAGCTACCTCCAGGAAAGCCTGGAGTTGGAGACGTGTCCAGACCTT
 TTAGCCACCCATACACTCCTCCAGCCCTCCTCCAATAGCACCTTAGCCCGGGCTGAAAGC
 ACTTCTTCAATATCATCAACCAATTCCTGAGCGCAGCCACCCTCCACAGTTGAGAATGA
 10 ACAGSCTTCCCTCGTTTGGTTTGACAGAGGAAAGTTTATTTGACTTTTGAAGGTTCTTCCA
 GGGGACCCAGTCTCTAACTATGGGGGCCAGGACACCTCCCGGTTGCAGCAGCATTACACA
 GAAACTGTCAATGCCACTTCAAAGGAGCAGATCCAAGCAAATGCATTGTTAAGATCACGGG
 AGAAATGGTGTGTCTTTCCCTGCTGGCATCACCAGACACTTTGCCAACAACCCATCCCCAG
 CTGCTCTGACTTTTCGAGTGATAAAATCCAGCAGGTTAGAGCAGTCTTGCAGAACCCAG
 15 CTCTCTGCTGCGATAACACACAAAATGATGCCAATACCAAGGAATCTGGGTAACCATGCC
 AAATTTGATGACCCACCTGAAGAAGGTCTCTGAACAAAAACCCAGGCTACATATTAACAATG
 TGGACATGCTCAAGTATCAGGTGTGAGCCAGGCATTGAGTCCACACCTCTGAACTTGGCG
 GTGAACTGGCGCTGTGAGCCTTCCAGCACTGACCTGCGCATAGATTATAAGTACAACACGGA
 TGCCATGTCCACCGCAGTGGCCCTTAACAACGTGCAGTTCCTGGTCCCATTGATGGAGGAG
 20 TGACCAAGCTCCAGGCTGTCTTCCCTCCAGCAGTCTGGAATGCTGAACAACAAGAATATTA
 TGGAAGATTCCCTGATATCTCCAGAAAGTCAGAAAATGGAGGCGTAGGTTCTTTACTGGCAAG
 ATTTCAATTAGCCGAAGGCCAAGCAAACCTTCCCCTGGTCTGTCAGTTCACGAGTGAAG
 GGAGCACTCTGTCTGGCTGCGACATGAGCTTGTTCGGAGCAGGGTACGGGTTTTCACTCATC
 AAGAAGAGGTTTGTCTGCAGGAAAATACTTGGCCGATAACTAATAAAAATGTCATGCAAGGATT
 25 TTGAAGATCCATGTCCTGGGAACTGTTGTCTGAGAGACATATTTAATCTGGTTTGGAGAA
 AACAAACCAACCGATGTCTGTACGTGGGCTCTGTGAGCTGGAAGGTCCCAGGCTTTAGCCGT
 GATTTCCACACCCAGTACAAGGAGGATCAGTCTACAGTACTTACTTCTAGGTGTACTATT
 GTTAAATGGTTTTTAAAATGTAATTAATGTAATTTGTAATTTGTAACCTTACCTTCAATCCAGCAG
 TTAGACACCTGAGTTTTTAGCTTTTTTTTTTCCATTCCTGAAACCGGATGTAATTTAAACTCGCGT
 30 ATGTAATTTAATAGTAGTACTGTGCAATGGCACAATGCTTACAGAGATACAGTGCATTTTG
 TCAATATATAAAAATTTAAATATAATGTTGATAGTTACCATAAAGGGGGTGCACACATCAAG
 AACCTTAAATGGAACCAGAAAACAAGCAAACAAAACAAAACAAAACAAAACAAACCTTACTT
 TTCTTCACTCCTTATTACATTTTCTCTAGAGCTAAAGAACTTCTAGCTTCGGTTTAGTGG
 GTTAAATTCAGAACTATTTTCAAGAAAAAATAATTTCTGAAGTTACAGCATATTTCAAAGA
 35 GAAGCATTAAATACCCTTTTTTAAAAGCTTTTTTTTTTCAAACCGCAAATTTCAATAAAAATGC
 AAACGTGTAAACAGGGCTCTTATTTTTATAACTTGTGTAAAAGGGGAAAATCAATTCATA
 TTTAAAGTTTAAAGTAGTATTAATTTATATCCAAGAGTGAAGAGGATGTTGAAATCTTACCTG
 ACCCATGCCCCCTTCTTTGCGAGTTTAGCAAATGTTGAGATTGCTAAATCATCAGATTAAGC
 CAACTTGATTTTTTAAAGTTTCAAGACTTTCTGAAGCTGAACTGGTTAAAACCTTTTGCACAAT
 40 TGCTTGGAACGGAGGGGGAGGGGCTCTCTGGTCCAGCACAGGTACCTTGTCTTCTCCCTAC
 TCACAAGAATCAAAACAATGAAAGTCAAGAACCACAGAGGGGGGAAATAGTTCCCTGTTCA
 GTCCAAAAGGAGAACTTTAAACTTATCATTTACGTCTTTGGGGGAAGGAAGAAATAAGCTTTA
 TAAGTGAATCCTTATTCACCTTGTGTCTTATGAATGTTTTTTCGGGGTGACTTTAAGATTCAT
 45 TGTATACATGTGCGAGTCTCTGCTATTCTTGGGGAGTTGAAAGCAGAGCCAGGCCAGTGGCC
 TTGAAGTTCAGTAAATGCCACAGTCTGGGGCAAAGGTAGGCATGAGGGTTCTGCCCTCAG
 CACAGGAATCAGAGCAGTGTCTTGTAAAGTCTAAAGATTAAGTCTTCCAGTAAGCCACAAGT
 TATTTTGTAAACAGAGTTGGGGAGTTTTGGCACTCGCTGCTGACTTTTCAATTTGTATCCACTC
 AAATGGAGTCTTCAACTCTTTTCAACTTAGAATCAAATTAATTTTTTTTTTTTTTTTTTTTT
 50 TTTTTTACACAAGGTTTACTCTGTGTAAGTGTCTGCTGGATGTTCTGGAACTCTTTTTGTAGACC
 AGGCTGGCTTCGAACTCAGAGAGATCCACCTGCCTGTGCTCCCCAAGTGTGGGATTAAGG
 CGTGTGCCACCATGCCTGGCTTAGATTAATTTTTTAAAGTCTTACTTACCAGTGAAGTTGT
 GATTGGCAGTTGTTTCGAGAGAGCTTTGTAGCTTAATCTATGTTCTCTTCAATCAATGCTTG
 CTACCAAAAAGAAATGTCCAAAATGATCTATTTTTCTGGGAACAATTCATCTATTTAAATAGG
 55 CTCTTGCTAGTTCCCCAAAGCAGCTGTCTTTGAAGGTTTTTTTTGAACAAAATAATTTTTT
 CACAAAAGTATTGGTTTTGAAATCAAATAGAGAAAATAAAATGTAATTTTAAATCTAATGG
 AACATGAGGAAATGAAAAAATTAAGCCAATGGAGAGTAAAAGCAGAAAAAATGAAACTTA
 CCTAGAAATGTGATTATATATGTTTTTAAAGTAGTCAATTCATGGAAAAATATTGAATATTA

5 CACAAAGCATATTAATAATATGTAAATATTACTGTTTCTCATGTCTTTCTCTTTATATCTTA
 TTTTATATAGTTTTAGAAATGAATTGGTCATTAAATACAGTGTCTTTCTTTCCAAAGAATAATTT
 TGGTGTATTTGTAATAATGTAATTTAAAGATAGAGACTTGAATAGTCTCTAACATTATCCAAA
 TGTCTTAGGAACCAAATTCAAAGCTGTGAAGAAAGCTTGCAATCCCTGAATTGGCTTTTGT
 10 GAAATGGAATGACGGTGGGTAATCTCAAAATTCAGACTTGAATAGTCAGAGCTGAAGTGGGG
 AATGGGTGGTTCCTTCTGGTTCAGAAAATAGGTCAAATAACAGCATTGCTCGCATCAGGGA
 TGGAGATGTTGGTGTATGTTGGTTTTACTCTCGCAGGCTTTCGTCTCCTGTTGAAGGTGTAT
 CTGTAGCCCAGTGGGATAAGAGTTCATGTTCTGAGATGTGGTCTAGACAAGGCAGGCAAGG
 TTTCAAGTCATCAATACCTATCAGGTCAGGTTCCCTTTTGTCTATACAAAATGGGTTAGCTCA
 15 TAGCCAGATGGTTTGCAGGACAGTGAGCTAAATTAGGACAAGATTCTGGTTAGCCAAAGAGC
 TGTTTCCTAAGCACTCTGATTTTTTTTTTAAAGCTGATAGAAAAGTGAATGTTCTATTTTTGA
 CGACATGGAAGTATGTTTTCCCTCTTCAAATAAATCCCTTATTTTTATGAAATTTTCAAAAA
 TAAATCTTGTTTAAAAATAGTCTGAATGTTATCATAGTTGGAACCTGGCAATTAATAATTTG
 AAATCTATGAGATGTATCTCCAGCTAAAAATGGCAATCCCTGTATGCTATCTGGGGCTCAG
 20 TTTACCTCTAAGGAAGACTGTGAGAGTCAAATGGTTTTGAGTGACGGGAAAGTCAAAGGGC
 AAATGTTTTGTGCTTTTTTCTTTTCTGTCTTATATACTTCTTCTTGGTCTCAGAATGCAAAG
 TATCAGAGCCATAGTTACACACATTTCCACTTTTAACGCTTCTTTTGAAGGAAGCAGATCCA
 CTTTTGCCCGCCACTCATGCCTGTGTGCAGACTCAGACGAGTCCCTGCCCTCTTACAGCC
 TTTGGGGTGAGAGGGGAGCCATATGTAAGTAGTTTTCAAGCTTTTCTTAATGGGACTTTTTCT
 25 TTTTCTAATAAAAAATCATGCCTGGAATCCTGTAAAGATTGTTGCCTGGCTGTGAAGGGGCTTC
 TCCAGATCCTGAAATATAGCATCACAAATACGTAATGACTCCCAGTGGATCTCCCAGCTCTG
 AAGACTTGCTCTTCTACTTTCACATGTGTAGCCACGACGATCAGCTGGCACACAGTACAATTA
 GCTGTGTAGTGAGTGCTCCCCAGCTATCAGTCATGAAACATATCACTTTGCTCAACCTGTTT
 TAAAAAAGCTCCAAAATGGTAAAAATGCTTTTTCAGTCTTTGTTTTCCCAATAATGGTATTG
 30 AGGCCAAGCTGATTAACCTCCCCCAAAGTGGTACCACAGCTGGTAACGACCCCAATGATCC
 TGAAAAAATGGAATGAGTACCTTGCTGTTTCRTTTAGTYYATTTTGGGAAAATAATCCATT
 TGAATGTCAAGATAAAAAGGCACCAGGAAAAGTCTCATTGGAAGGATTAAGATGAGCCTG
 GTAAGATGTTAAGATGTAAGATGTTAAGATGTGTTACTGTAAAAAAGCTT [SEQ
 ID NO:3].

The corresponding amino acid sequence is as follows:-

35 MMEGLKRRTRKAFGIRKKEKDTDSTGSPDRDGMQPSHELPHYHKAECAREGGNKASKKSNG
 APNGFYAIDWERYNSPELDEEGYSIRPEEPGSTKGKHFYSSSESEEEEEESHKKFNIKIKPL
 QSKDILKNAATVDELKASIGNIALSPSPVRKSPRRSPGAIKRNLSSSEVARPRRSTPTPELT
 SKKPLDDTLALAPLFGPPLESFAFDGHKTEVLLDQPEIWGSGQPVNPSMESPKLARPFPTGTP
 PPLPKTVPATPPRTGSPPLTVATGNDQAATEAKIEKLPSISDLDSIFGPVLSPKSVAVNTEE
 40 TWVHFSASPEHVTPELTPREKVVTPPAASDIPADSPTPGPPGPPGSAGPPGPPGPRNVSP
 LNLBEEVQKKVAEQTFIKDDYLETLSSPKCEGLGQRATPPPPPPPTYRTVSSPGPGSGSGTG
 TASGASSPARPATPLVPCSCSTPPPPPPRPPSRPKLPPGKPGVDVSRPFSPIHSSSPPI
 APLARAESTSSISSTNSLSAATPTVENEQASLVWFDRGKFYLTFFEGSSRGPSPLTMGAQDT
 LPVAAAFTEFVNAYFKGADPSKIVKITGEMVLSFPAGITRHFANNPSPAALTFRVINSSRL
 EHVLPNPQLLCDNTQNDANTKEFWVNMPNLMTHLKKVSEQKPQATYYNVDMMLKYQVSAQGI
 45 QSTPLNLAVNWRCEPSSDLDLIDYKYNTDAMSTAVALNNVQFLVPIIDGGVTKLQAVLPPAVW
 NAEQQRILWKIPDISQKSENGVGSLLARFQLAEGPSKPSPLVVQFTSEGSTLSGCDIELVG
 AGYGFSLIKRFAAGKYLADN [SEQ ID NO:4].

EXAMPLE 9***AGT-121 Taqman tissue distribution***

Tissue distribution of AGT-121 was investigated by Taqman PCR in multiple tissues of *P. obesus* (Figure 3). Highest levels were seen in the brain with very low levels also evident in the spleen.

EXAMPLE 10***AGT-121 - Clontech MTN human RNA blot***

10

Tissue distribution of AGT-121 in human tissues was also examined by Northern analysis of a Clontech multiple tissue RNA blot. A specific band of approximately 6 kb was seen in the brain (Figure 4). AGT-121 is thought to be brain-specific.

15

EXAMPLE 11***AGT-121 alleles are associated with obesity***

The insertion and deletion alleles described in the original patent are associated with obesity. Eighty lean and obese individual *Psammomys obesus* were genotyped for the presence of the deletion, or the insertion, or both. Diabetic animals were not considered. The genotype is significantly associated with the obesity phenotype seen in *P. obesus*. The results are shown in Tables 4 and 5.

TABLE 4 Summary of results

25

		Phenotype		Total
		Lean	Obese	
Genotype	Insertion	24	9	33
	Heterozygote	17	15	32
	Deletion	5	10	15
Total		46	34	80

TABLE 5 Chi squared tests

	Value	df	Asymp. Sig. (2-sided)
Pearson Chi Square	6.967	2	.031
Likelihood Ratio	7.092	2	0.29
Linear-by-Linear Association	6.879	1	.009
No. of valid cases	80		

EXAMPLE 125 ***AGT-121 gene expression in energy restricted hypothalamus***

Oligonucleotide primers were designed in the coding sequence of *Psammomys obesus* AGT-121. Expression of AGT-121 was analyzed in energy restricted hypothalamus. Positive correlations were seen with body weight in control animals, change in glucose in all animals and subscapular fat mass in all animals (Figures 5-8).

EXAMPLE 13***AGT-121 sequence homology***

15 The AGT-121: The ISR protein shows strong homology at both the nucleotide and protein level to human hypothetical protein DKFZp761D221 (DKFZp761D221) [Accession: NP_115667]. This protein is predicted to contain the pfam00928.5, Adap_comp_sub domain which is identified as adaptor complexes medium subunit family. This family also contains members which are cocatomer subunits. This gene has been localized to human
20 chromosome 1p31.2.

EXAMPLE 14***Partial sequence of Psammomys obesus AGT-122***

25 AGT-122 was identified using differential display PCR of liver cDNA from diabetic and non-diabetic *Psammomys obesus*.

The partial nucleotide sequence is as follows:-

5 TCGCGGATCCAGACGCTGCGTTTGCTGGCTTTGATGAAATTTTAAATTTTCAATATCAGG
 AATGTTTAACTATGCCATGAATTTATGGTAGTCAAGGTTGGAAGGCAGGGGAGAGGACACA
 GGGAGTAAAGGCACTTGCCCCAAGCCTTACAACCTGAATTCATCCCAGAGTGCCTAATG
 GTTGAAGGACGGAAC TGAATATCTCTAGCTGTCCTCTATCCTCCACAGATACACAGTGAAT
 GCATCAACGTAAAAAATTACAGCTAGAAATAATGTCGTGCCATTTCATTGTATTTTACATTN
 10 GTNCATCTTNGNTTTTCCATANTAAAAATGCTNAGACATACCACTTAAAAAAAAAAGCTT
 [SEQ ID NO:5].

EXAMPLE 15

AGT-122 gene expression

15 There was a significant difference in AGT-122 gene expression in the fed state between
 Group A compared to Group B ($p=0.001$) and Group C ($p=0.005$) animals (Figure 9). In
 the fasted state there were no significant differences between the groups. Within the groups
 of animals, significantly increased expression was seen only in the Group B fasted animals
 ($p=0.009$). When data from all groups were pooled, no significant differences were seen
 20 (Figure 10).

Expression of AGT-122 in grouped fasted animals showed no association with body
 weight, glucose, or insulin. Expression of AGT-122 in fed animals showed a significant
 negative correlation with body weight ($p=0.005$; Figure 11), glucose ($p=0.003$) and insulin
 25 ($p=0.015$).

EXAMPLE 16

AGT-122 sequence homology

30 The AGT-122 sequence shows significant homology with a number of regions on different
 mouse chromosomes. There was no homologous sequence on the public database
 (BLASTN version 2.2.1).

EXAMPLE 17***Partial sequence of *Psammomys obesus* AGT-422***

AGT-422 was identified by Suppression Subtractive Hybridization (SSH) [also referred to
5 as Representational Difference Analysis (RDA)] of liver cDNA from diabetic and non-
diabetic *Psammomys obesus*.

The partial nucleotide sequence is as follows:-

10 CCCTATCCGCTACCCCTGGGAGGGACACAAAAACACATTTTGTGTTTTTGAAAAAAGTGG
 GTCACCAGACTCTTGTATTGTCTTCTTGGACTTCTCTCAGGAACACTCAGGACTCTCCCCA
 CACAACACCGTTCTTGAACCGTTCTAACAAATGTTTAAAGTGGTTTCCTTTGAACCACATT
 AAATTTAGTTTAAAGCAGTCACCAGTGGGCTAGCAGTTCTGGGTTGGGCAGCACATCTTGTA
 15 CAAGCTCTTCCATCTGCCAGGATCACCACCTCTCTGACTTGCACATTTGTGGGTTCCCCAC
 AGACGAATGGGATGAGTGAAAGAGTGAGTATGTTCTGTTGGGCCTTCAGTAACAGAAGACT
 GATTCAGAAAGTAGCACACGTCACATTTTCTGTAGGTTGGTTTGTGTTTAGTTTCATTTTGTG
 ATTTGTGGAACAAAA [SEQ ID NO:6].

EXAMPLE 18***AGT-422 gene expression***

AGT-422 was normally distributed. One way ANOVA with an LSD *post hoc* test found
gene expression tended to be higher in fed Group A animals than fed Group C (p=0.068).
Gene expression was significantly greater in fed Group A animals than fasted Group A
25 (p=0.002), fed Group B animals than fasted Group B (p=0.014) and fed group C animals
than fasted group C (p=0.039) [Figure 12]. An independent samples T test found AGT-422
gene expression greater in fed animals than fasted animals when group data were
combined (p<0.001; Figure 13).

EXAMPLE 19***AGT-422 sequence homology***

The AGT-422 sequence shows sequence homology to *Rattus norvegicus* clone CH230-
213K1. The full gene and open reading frame are yet to be identified and a human
35 homolog is also as yet undetermined.

EXAMPLE 20***Partial sequence of *Psammomys obesus* AGT-123***

5 AGT-123 was identified using differential display PCR of hypothalamic cDNA from diabetic and non-diabetic *Psammomys obesus*.

The partial nucleotide sequence is as follows:-

10 TGAGAGTCCATCTCAGCTTATTTTCATTGAGATGTTTTGATTAAGAAGTATGACTAGATTAA
 AAAATTCTATATAGCTTGGCATTGTTGATAGTTTATATATTTCACTGATTTCTGGTCCCTT
 GAAAGTTACTTGGTGATCAACATAGTGTAGTGAAAGGATTGGGATGGACATTAACAAAAA
 AAGCTT [SEQ ID NO: 7]

15

EXAMPLE 21***AGT-123 gene expression***

Hypothalamic AGT-123 expression tended to be increased with fasting in Group A animals ($p=0.06$) and was significantly increased with fasting in Group B and Group C
 20 animals ($p=0.02$ and $p=0.01$, respectively) [Figure 14]. When all fed and fasted animals were combined, the fasted animals had significantly increased expression compared to fed animals ($p=0.001$) [Figure 14]. AGT-123 expression was not correlated with glucose or insulin concentrations. There was a tendency for a relationship between AGT-123 expression and body weight, although this was not statistically significant ($p=0.08$).

25

EXAMPLE 22***AGT-123 sequence homology***

The AGT-123 sequence matches three mouse expressed sequence tags
 30 (gb|BG797393.1|BG797393 ic14h03.x1 Kaestner ngn3 wt Mus musculus;
 gb|AI661150.1|AI661150 va01a02.x1 Soares mouse lymph node NbMLN;
 dbj|BB257743.1|BB257743 BB257743 RIKEN full-length enriched, 7 d) however, the corresponding gene has not yet been identified (BLASTN version 2.2.1).

- 64 -

EXAMPLE 23***Partial sequence of *Psammomys obesus* AGT-504***

5 AGT-504 was identified using Amplified Fragment Length Polymorphism (AFLP) screening of genomic DNA from diabetic and non-diabetic *Psammomys obesus*. It was found to be expressed in the liver of diabetic and non-diabetic *Psammomys obesus*.

The partial nucleotide sequences are as follow:-

10

Genomic DNA:-

15

TGGN TACTCTTGNAAGCACCTTGAAAGTTCAGCCTGCTAACTTACCTTTTTAGCTTTAGAT
 TGCTTAGATATTCAAATGAGAGTGTGGTGCAAATCCTGATTACAAGGAGTTTGAGTTTGGGA
 GTGATTGGCAATGCACTTGTGAGGCTGTGTGCCTATGGTCCTAGGACTTAGGAGGCAGGGA
 TAGAAGGACCAGGTGCTGAAAGACAGCCTTGGCTAGTTAGTGGACAGATACATAAATGTAC
 TGCATGAGATTCTTTCAGAATAACAACCTCCTTTTTAAAGAAGTTACTTCTGACATGGAATC
 TGTTCCTGCTTTTGGATCACTACCCCCTGGTGGGACACCTTTGCCAGACCATGGAGGAAG
 AACTGTCTTGAT [SEQ ID NO:8].

20

cDNA:-

25

AACGTGAGCTTTTTGGAAGGCCAGANAATTTAAGGAAAGTGTCCCGGCAAATCCTGATTA
 CAAGGAGTTTGAGTTTGGAGTGATTGGCAATGCACTTGTGAGGCTGTGTGCCTATGGTCCT
 AGGACTTAGGAGGCAGGGATAGAAGGACCAGGTGCTGAAAGACAGCCTTGGCTAGTTAGTG
 GACAGATACATAAATGTACTGCATGAGATTCTTTCAGAATAACAACCTCCTTTTTAAAGAAG
 TTACTTCTGACATGGAATCTGTTCCTGCTTTTGGATCACTACCCCCTGGTGGGACACCTT
 TGCCAGACCATGGAGGAAGAACTGTCTTGATGGGANN [SEQ ID NO:9]

30

EXAMPLE 24***AGT-504 gene expression***

Hepatic AGT-504 expression was normally distributed and ANOVA with LSD *post hoc* analysis showed that Group C animals had significantly higher AGT-504 gene expression
 35 compared to both Group A (p=0.014) and Group B (p=0.02) animals (Figure 15).

EXAMPLE 25***Amplified fragment length polymorphism (AFLP) technique***

The AFLP technique is based on the amplification of subsets of genomic restriction
5 fragments using polymerase chain reaction (PCR). DNA is cut with restriction enzymes
(*EcoRI* and *MseI*) and double-stranded adapters are ligated to the ends of the DNA
fragments to generate template DNA for amplification. The sequences of adapters and the
adjacent restriction site serve as primer binding sites for subsequent amplification of the
restriction fragments. Selective nucleotides are included at the 3' ends of the PCR primers,
10 which therefore prime DNA amplification only from a subset of the restriction fragments.
This method will identify sequence differences in the restriction sites that are associated
with the obesity/diabetes phenotype.

AFLP was performed using the GibcoBRL "AFLP Analysis System I" and "AFLP Starter
15 Primer" Kits according to the manufacturer's instructions.

Six genomic DNA pools of each group of *Psammomys obesus* (n=15) were used in an
AFLP screen of 256 primer pairs, which equates to a genomic scan at a density of
approximately 1.4 cM. The animals were divided by sex and then into three groups
20 corresponding to lean (Group A), obese (Group B) and obese/diabetic (Group C).

The PCRs were performed in 20 µl under the following conditions: one cycle at 94°C for
30 s; 65°C for 30 s; and 72°C for 60 s, then for each consecutive cycle the annealing
temperature was lowered by 0.7°C for 12 cycles. This gives a touchdown phase of 13
25 cycles. This was followed by 23 cycles at 94°C for 30 s, 56°C for 30 s and 72°C for 60 s.

Once amplified, the fragments were separated on a 6% (w/v) polyacrylamide gel to
visualize the (typically) 50-150 bands. Those bands that were deemed to be different
between the groups of animals were excised from the gel. Re-amplification of the band of
30 interest was performed using the following PCR conditions: 94°C 2 min, 40 cycles of
(94°C 30 s; 54°C 30 s; 72°C 60 s); 72°C 5 min and the following primers: F 5'-GTA GAC

- 66 -

TGC GTA CCA ATT C-3' [SEQ ID NO:10] and R 5'-GAC GAT GAG TCC TGA GTA A-3' [SEQ ID NO:11]. The amplified bands were sequenced with Applied Biosystems Big Dye sequencing kit.

5

EXAMPLE 26***Primers***

Primer and probe sequences for amplification and analysis of each gene (shown in the 5' to 3' direction).

10

SYBR Green analysis

AGT-119

Set 1

Forward: ggattatcgtgaccagataggagc [SEQ ID NO:12]

15 Reverse: acgcatcttggtgggctaatag [SEQ ID NO:13]

Set 2

Forward: cgcaaccaaattagccagtg [SEQ ID NO:14]

Reverse: gcatcttggtgggctaatagacat [SEQ ID NO:15]

20

AGT-120

Forward: acccagatgctggctgact [SEQ ID NO:16]

Reverse: ctggccaccagtcagtgaataa [SEQ ID NO:17]

25 AGT-121

Forward (insertion): aaaacatgagagaagccataactaattca [SEQ ID NO:18]

Forward (deletion): cacaaaacatgagataactaattcataagtga [SEQ ID NO:19]

Reverse: tgaaaccaagatagcaciaaacgaa [SEQ ID NO:20]

30

- 67 -

AGT-122

Forward: catcccagagtgcctaattggtt [SEQ ID NO:21]

Reverse: acgttgatgcattcactgtgtatct [SEQ ID NO:22]

5 AGT-422

Forward: cagtcaccagtgaggctagca [SEQ ID NO:23]

Reverse: cctggcagatggaagagctt [SEQ ID NO:24]

AGT-123

10 Forward: gcttggcattggtgatagtttatatatttc [SEQ ID NO:25]

Reverse: cactacactatggtgatcaccaagtaactt [SEQ ID NO:26]

AGT-504

Forward: gaatctggtgctgcttttgg [SEQ ID NO:27]

15 Reverse: ctccatggtctggcaaaggt [SEQ ID NO:28]

Taqman analysis

 β -actin Forward: gcaaagacctgtatgccaacac [SEQ ID NO:29] β -actin Reverse: gccagagcagtgatctctttctg [SEQ ID NO:30]

20 Probe: FAM-tccgggtccacaatgcctgggaacat-TAMRA [SEQ ID NO:31]

Cyclophilin Forward: cccaccgtgttctttcgaca [SEQ ID NO:32]

Cyclophilin Reverse: ccagtgctcagagcagaaa [SEQ ID NO:33]

Probe: FAM-cgcgtctccttcgagctgtttgc-TAMRA [SEQ ID NO:34]

25

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

30

BIBLIOGRAPHY

Altschul *et al.*, *Nucl. Acids Res.* 25: 3389, 1997.

Australian Institute of Health and Welfare (AIHW), Heart, Stroke and Vascular diseases, Australian facts. AIHW Cat. No. CVD 7 Canberra: AIHW and the Heart Foundation of Australia, 1999.

Ausubel *et al.*, "Current Protocols in Molecular Biology" John Wiley & Sons Inc, Chapter 15, 1994-1998.

Barnett *et al.*, *Diabetologia* 37: 671-676, 1994a.

Barnett *et al.*, *Int. J. Obesity* 18: 789-794, 1994b.

Barnett *et al.*, *Diabete Nutr. Metab.* 8: 42-47, 1995.

Bonner and Laskey, *Eur. J. Biochem.* 46: 83, 1974.

Bouchard, The genetics of obesity. Boca Raton: CRC Press, 1994.

Collier *et al.*, *Ann. New York Acad. Sci.* 827: 50-63, 1997a.

Collier *et al.*, *Exp Clin. Endocrinol. Diabetes* 105: 36-37, 1997b.

De Looper, M and Bhatia K, *Australia's Health Trends 2001*. Australian Institute of Health and Welfare (AIHW) Cat. No. PHE 24. Canberra: AIHW, 2001.

Douillard and Hoffman, Basic Facts about Hybridomas, in *Compendium of Immunology* Vol. II, ed. by Schwartz, 1981.

Kohler and Milstein, *Nature* 256: 495-499, 1975.

Kohler and Milstein, *European Journal of Immunology* 6: 511-519, 1976.

Koopmans, Experimental studies on the control of food intake. In: Handbook of Obesity, Eds. GA Bray, C Bouchard, WPT James pp 273-312, 1998.

Kopelman *et al.*, *Int. J. Obesity* 18: 188-191, 1994.

Kopelman, *Nature* 404: 635-643, 2000.

Marmur and Doty, *J. Mol. Biol.* 5: 109, 1962.

Mokdad *et al.*, *JAMA*. 282(16): 1519-1522, 1999.

Mokdad, *Diabetes Care* 24(2): 412, 2001.

Must *et al.*, *JAMA*. 282(16): 1523-1529, 1999.

National Health and Medical Research Council, Acting on Australia's weight: A strategy for the prevention of overweight and obesity. Canberra: National Health and Medical Research Council, 1996.

Ravussin, *Metabolism* 44(Suppl 3): 12-14, 1995.

Russek, M., A hypothesis on the participation of hepatic glucoreceptors in the control of food intake. *Nature* 200: 176, 1963.

Shafrir and Gutman, *J. Basic Clin. Physiol. Pharm.* 4: 83-99, 1993.

Stellar, *Psychol. Rev.* 61: 5-22, 1954.

Walder *et al.*, *Obesity Res.* 5: 193-200, 1997a.

Wolf and Colditz, *Obes. Res.* 6: 97-106, 1998.

Zimmet, *Diabetes Care* 15(2): 232-247, 1992.

CLAIMS

1. A nucleic acid molecule comprising a sequence of nucleotides encoding or complementary to a sequence encoding an expression protein or a derivative or homolog thereof wherein said nucleic acid molecule is differentially expressed in stomach, liver and/or hypothalamus tissue in obese animals compared to lean animals or in fasted animals compared to fed animals or in diabetic animals compared to non-diabetic animals.
2. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO:1 or a nucleotide sequence having at least about 30% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or its complementary form under low stringency conditions.
3. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO:2 or a nucleotide sequence having at least about 30% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:2 or its complementary form under low stringency conditions.
4. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO:3 or a nucleotide sequence having at least about 30% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:3 or its complementary form under low stringency conditions.
5. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO:5 or a nucleotide sequence having at least about 30% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:5 or its complementary form under low stringency conditions.
6. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO:6 or a nucleotide sequence having at least about 30% similarity thereto or a nucleotide sequence capable of

hybridizing to SEQ ID NO:6 or its complementary form under low stringency conditions.

7. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO:7 or a nucleotide sequence having at least about 30% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:6 or its complementary form under low stringency conditions.

8. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO:8 or a nucleotide sequence having at least about 30% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:6 or its complementary form under low stringency conditions.

9. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises a nucleotide sequence as set forth in SEQ ID NO:9 or a nucleotide sequence having at least about 30% similarity thereto or a nucleotide sequence capable of hybridizing to SEQ ID NO:6 or its complementary form under low stringency conditions.

10. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:1.

11. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:2.

12. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:3.

13. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises the nucleotide sequence which encodes the amino acid sequence set forth in SEQ ID NO:4.

14. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid

molecule comprises the nucleotide sequence set forth in SEQ ID NO:5.

15. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:6.

16. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:7.

17. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:8.

18. The isolated nucleic acid molecule of Claim 1 wherein the nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:9.

19. An isolated molecule comprising a sequence of nucleotides or amino acids encoded by a nucleic acid molecule which is differentially expressed in stomach, liver and/or hypothalamus tissue in obese animals compared to lean animals or in fasted animals compared to fed animals or in diabetic animals compared to non-diabetic animals.

20. The isolated molecule of Claim 19 encoded by a nucleic acid molecule as set forth in SEQ ID NO:1 or a nucleotide sequence having at least about 30% similarity to SEQ ID NO:1 or a nucleotide sequence capable of hybridizing to SEQ ID NO:1 or its complementary form under low stringency conditions.

21. The isolated molecule of Claim 19 encoded by a nucleic acid molecule as set forth in SEQ ID NO:2 or a nucleotide sequence having at least about 30% similarity to SEQ ID NO:2 or a nucleotide sequence capable of hybridizing to SEQ ID NO:2 or its complementary form under low stringency conditions.

22. The isolated molecule of Claim 19 encoded by a nucleic acid molecule as set forth in SEQ ID NO:3 or a nucleotide sequence having at least about 30% similarity to

- 74 -

SEQ ID NO:3 or a nucleotide sequence capable of hybridizing to SEQ ID NO:3 or its complementary form under low stringency conditions.

23. The isolated molecule of Claim 19 encoded by a nucleic acid molecule as set forth in SEQ ID NO:5 or a nucleotide sequence having at least about 30% similarity to SEQ ID NO:5 or a nucleotide sequence capable of hybridizing to SEQ ID NO:5 or its complementary form under low stringency conditions.

24. The isolated molecule of Claim 19 encoded by a nucleic acid molecule as set forth in SEQ ID NO:6 or a nucleotide sequence having at least about 30% similarity to SEQ ID NO:6 or a nucleotide sequence capable of hybridizing to SEQ ID NO:6 or its complementary form under low stringency conditions.

25. The isolated molecule of Claim 19 encoded by a nucleic acid molecule as set forth in SEQ ID NO:7 or a nucleotide sequence having at least about 30% similarity to SEQ ID NO:7 or a nucleotide sequence capable of hybridizing to SEQ ID NO:7 or its complementary form under low stringency conditions.

26. The isolated molecule of Claim 19 encoded by a nucleic acid molecule as set forth in SEQ ID NO:8 or a nucleotide sequence having at least about 30% similarity to SEQ ID NO:8 or a nucleotide sequence capable of hybridizing to SEQ ID NO:8 or its complementary form under low stringency conditions.

27. The isolated molecule of Claim 19 encoded by a nucleic acid molecule as set forth in SEQ ID NO:9 or a nucleotide sequence having at least about 30% similarity to SEQ ID NO:9 or a nucleotide sequence capable of hybridizing to SEQ ID NO:9 or its complementary form under low stringency conditions.

28. The isolated molecule of Claim 19 wherein the molecule is a protein.

29. The isolated protein of Claim 28 encoded by a nucleotide sequence set forth in

- 75 -

SEQ ID NO:1.

30. The isolated protein of Claim 28 encoded by a nucleotide sequence set forth in SEQ ID NO:2.

31. The isolated protein of Claim 28 encoded by a nucleotide sequence set forth in SEQ ID NO:3.

32. The isolated protein of Claim 28 comprising the amino acid sequence set forth in SEQ ID NO:4.

33. The isolated protein of Claim 28 encoded by a nucleotide sequence set forth in SEQ ID NO:5.

34. The isolated protein of Claim 28 encoded by a nucleotide sequence set forth in SEQ ID NO:6.

35. The isolated protein of Claim 28 encoded by a nucleotide sequence set forth in SEQ ID NO:7.

36. The isolated protein of Claim 28 encoded by a nucleotide sequence set forth in SEQ ID NO:8.

37. The isolated protein of Claim 28 encoded by a nucleotide sequence set forth in SEQ ID NO:9.

38. An isolated protein selected from the list consisting of:-

- (i) a protein encoded by a nucleic acid molecule which molecule is differentially expressed in hypothalamus or muscle tissue of obese

- 76 -

animals compared to lean animals or a derivative, homolog, analog, chemical equivalent or mimetic thereof;

- (ii) a protein encoded by a nucleic acid molecule which molecule is differentially expressed in liver tissue of fasted animals compared to fed animals or a derivative, homolog, analog, chemical equivalent or mimetic thereof;
- (iii) a protein encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:1 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- (iv) a protein encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:2 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- (v) a protein encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:3 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- (vi) a protein comprising an amino acid sequence substantially as set forth in SEQ ID NO:4 or a derivative, homolog or analog thereof or a sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;

- 77 -

- (vii) a protein encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:5 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- (viii) a protein encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:6 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- (ix) a protein encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:7 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- (x) a protein encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:8 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;
- (xi) a protein encoded by a nucleotide sequence substantially as set forth in SEQ ID NO:9 or a derivative, homolog or analog thereof or a sequence encoding an amino acid sequence having at least about 30% similarity to this sequence or a derivative, homolog, analog, chemical equivalent or mimetic of said protein;

- 78 -

- (xii) a protein encoded by a nucleic acid molecule capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO:1 or a derivative, homolog or analog thereof under low stringency conditions;
- (xiii) a protein encoded by a nucleic acid molecule capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO:2 or a derivative, homolog or analog thereof under low stringency conditions;
- (xiv) a protein encoded by a nucleic acid molecule capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO:3 or a derivative, homolog or analog thereof under low stringency conditions;
- (xv) a protein encoded by a nucleic acid molecule capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO:5 or a derivative, homolog or analog thereof under low stringency conditions
- (xvi) a protein encoded by a nucleic acid molecule capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO:6 or a derivative, homolog or analog thereof under low stringency conditions;
- (xvii) a protein encoded by a nucleic acid molecule capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO:7 or a derivative, homolog or analog thereof under low stringency conditions;
- (xviii) a protein encoded by a nucleic acid molecule capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO:8 or a derivative, homolog or analog thereof under low stringency conditions;
- (xix) a protein encoded by a nucleic acid molecule capable of hybridizing to the nucleotide sequence as set forth in SEQ ID NO:9 or a derivative, homolog or analog thereof under low stringency conditions;

- 79 -

(xx) a protein as defined in any one of paragraphs (i) to (xix) in a homodimeric form; and

(xxi) a protein as defined in any one of paragraphs (i) to (xix) in a heterodimeric form.

39. A method for modulating expression of one or more of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-423* and/or *AGT-504* in a mammal, said method comprising contacting *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-423* and/or *AGT-504* with an effective amount of a modulator of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-423* and/or *AGT-504* expression for a time and under conditions sufficient to up-regulate or down-regulate or otherwise modulate expression of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-423* and/or *AGT-504*.

40. A method of modulating activity of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-423* and/or *AGT-504* in a mammal, said method comprising administering to said mammal a modulating effective amount of a molecule for a time and under conditions sufficient to increase or decrease *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-423* and/or *AGT-504* activity.

41. A method of treating a mammal suffering from a condition characterized by one or more symptoms of obesity, anorexia, diabetes and/or energy imbalance, said method comprising administering to said mammal an effective amount of an agent for a time and under conditions sufficient to modulate the expression of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-423* and/or *AGT-504* or sufficient to modulate the activity of *AGT-119*, *AGT-120*, *AGT-121*, *AGT-122*, *AGT-422*, *AGT-423* and/or *AGT-504*.

42. A method of treating a mammal suffering from a disease condition characterized by one or more symptoms of obesity, anorexia, diabetes or energy

imbalance, said method comprising administering to said mammal an effective amount of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-423 and/or AGT-504 or *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-423* and/or *AGT-504*.

43. Use of an agent capable of modulating the expression of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-423 and/or AGT-504 or a derivative, homolog or analog thereof in the manufacture of a medicament for the treatment of a condition characterized by obesity, anorexia, diabetes and/or energy imbalance.

44. Use of an agent capable of modulating the activity of AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-423 and/or AGT-504 or a derivative, homolog, analog, chemical equivalent or mimetic thereof in the manufacture of a medicament for the treatment of a condition characterized by obesity, anorexia, diabetes and/or energy imbalance.

45. Use of *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-423* and/or *AGT-504* or derivative, homolog or analog thereof or AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-423 and/or AGT-504 or derivative, homolog, analog, chemical equivalent or mimetic thereof in the manufacture of a medicament for the treatment of a condition characterized by obesity, anorexia, diabetes and/or energy imbalance.

46. A composition comprising a modulator of *AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-423* and/or *AGT-504* expression or AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-423 and/or AGT-504 activity and one or more pharmaceutically acceptable carriers and/or diluents.

47. A method for detecting AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-423 and/or AGT-504 or a derivative or homolog thereof in a biological sample from a subject, said method comprising contacting said biological sample with an antibody specific for AGT-119, AGT-120, AGT-121, AGT-122, AGT-422, AGT-423 and/or AGT-

- 81 -

504 or their antigenic derivatives or homologs for a time and under conditions sufficient for a complex to form, and then detecting said complex.




Figure 1




Figure 2




Figure 3




Figure 4

3/8




Figure 5




Figure 6

4/8




Figure 7




Figure 8

5/8




Figure 9




Figure 10

6/8




Figure 11




Figure 12

7/8




Figure 13




Figure 14




Figure 15

- 1 -

SEQUENCE LISTING

<110> Autogen Research Pty Ltd (all other states other than US)
 International Diabetes Institute (all other states other than US)
 Deakin University (all other states other than US)
 Collier, Greg (US only)
 Zimmet, Paul (US only) Z
 Walder, Ken (US only)
 McMillan, Janine (US only)
 de Silva, Andrea (US only) M
 Windmill, Kelly (US only)

<120> A gene and uses therefor

<130> 2574822/EJH

<140> International
 <141> 2002-10-16

<150> US 60/330,149
 <151> 2001-10-16

<160> 34

<170> PatentIn version 3.1

<210> 1
 <211> 181
 <212> DNA
 <213> Psammomys obesus

<220>
 <221> misc_feature
 <222> (48)..(50)
 <223> n = any nucleotide

<220>
 <221> misc_feature
 <222> (52)..(52)
 <223> n = any nucleotide

<220>
 <221> misc_feature
 <222> (164)..(164)
 <223> n = any nucleotide

<400> 1
 aatgaaagaa ttgattgata cgcaaccaa ttagccagtg aggttagnnm cnggattatc 60
 gtgaccagat aggagccttg gaaaatgact aagaaaaatg aaaaacagcc taaaatgtca 120
 ttagcccaac aagatgcggtt aaaacgcctg gatcaagtta gaangcagaa aagcgaaagc 180
 c 181

- 2 -

<210> 2
 <211> 814
 <212> DNA
 <213> Psammomys obesus

<220>
 <221> misc_feature
 <222> (374)..(374)
 <223> n = any nucleotide

<400> 2
 gctgatggcg atgaatgaac actgcgtttg ctggccttat caattcccgc tttttcttgg 60
 atgaaaaaga ctaaccatga tcgggcccaa cggcggaagt cgcttttgtc accagtagtg 120
 atggtgccgg gatcaagtgc cacgattgag cgtttcaatt cactgattgc gatgcttaat 180
 aaagattcgc cgcaccctca cagtgtgtta aagattaaag tcatgaaaga tggcagttta 240
 aaatacaagg gcagcattaa tcgcggtgat aatgaaccct ttattgtgat tggttttgaa 300
 aataataaag atggctatag taatattaag aagcaagcaa gctggctaga tattgccttt 360
 tatgagatct cgcnaactta taaatttaac aactttaagg cctttggcca ttcaaatgga 420
 gggctgggtg ggacatattg gttagagcat tattattcag agtatgagtc agaaatcaaa 480
 atcaagcggg tgatgacttt ggcttcacca tttaactttg acgaagacaa tctgaatcac 540
 cggaccocaga tgctggctga ctttattaaa tatcggaaac gacttccaaa aacgctcaaa 600
 gtttattcac tgactgggtg ccagacctat gaatctgacg ggattgttcc tgaaaaatagt 660
 gtagccgcag ccaagtatat tttccaaaat caagtgaaga gctttatgga aattacggtt 720
 acgggtaagc agctaatac tcagatttac cgcaaatga acaagtagtg ctagtgatga 780
 atocaccact cactaaagat aataaaaaaa aaaa 814

<210> 3
 <211> 6317
 <212> DNA
 <213> Psammomys obesus

<400> 3
 cagactcctt ggaaattaag gaatgcaatt ctgccacat gatggaagga ctgaaaaaac 60
 gtacaaggaa ggcctttgga atacggaaga aagaaaaaga cactgactct acaggctcac 120
 cagatcgaga tggaatgcag cccagcccac acgagctccc ctacatagc aaagcagagt 180
 gtgcccgcaga aggagggaac aaagcttcga agaaaagcaa tggggcacca aatggatttt 240

- 3 -

atgCGGaaat	tgattgggaa	agatataact	cacctgagct	ggatgaagaa	ggttacagca	300
tcagacctga	ggaaccaggc	tctaccaaag	gaaagcactt	ttattcttca	agtgaatccg	360
aagaggagga	agaatcgcac	aagaagttca	atatcaagat	taaacccttg	cagtccaagg	420
acatccttaa	gaatgctgca	acagtagacg	agctgaaggc	ttccataggc	aacattgcac	480
tttccccttc	gcctgtgagg	aaaagtccga	ggcgcagccc	gggtgcaatt	aaaaggaact	540
tatccagtga	agaagtcgca	agaccaggc	gttccacccc	aactccagaa	cttacaagca	600
agaagcctct	ggacgacact	ctggcccttg	ctcccctctt	tggcccaccg	ttagaatctg	660
cttttgatgg	acacaagacg	gaagttcttt	tagatcagcc	tgagatatgg	ggttcaggcc	720
aaccagttaa	cccaagcatg	gagtcaccaa	agctagcaag	accttttccc	actggaaccc	780
ctccacctct	gcctccaaaa	actgtaccag	ccaccccgcc	tgggacaggc	tcccccttaa	840
cagtggcgac	aggaaatgac	caggcagcca	cagaggccaa	aattgagaaa	ctaccatcca	900
tcagtgacct	ggacagcatt	tttgcccccg	tgttgctccc	caagtctggt	gctgttaata	960
ctgaggagac	gtgggtccat	ttctctgatg	catccccgga	acatgttact	ccagagttga	1020
ctccaaggga	aaaggtggtg	accccaccag	ctgcatcaga	catcccagct	gactccccaa	1080
ctccaggccc	gcctggcccc	ccaggctcgg	caggtcccc	agggcctcct	ggtcctcgca	1140
atgtaccatc	tccgctcaat	ttagaagaag	tccagaagaa	agtcgctgag	cagaccttca	1200
ttaaagatga	ttacttagaa	acactctcat	ctcctaaaga	gtgtggggtg	ggacagagag	1260
caactccacc	tccccacca	ccaccacct	acaggactgt	ggtttcgtcc	cccggacctg	1320
gctcgggcag	tggtacgggg	accgccagtg	gtgcatcgtc	ccctgctcgg	ccagccaccc	1380
ccttagttcc	ttgcagctgc	tccaactcgc	ctccacctcc	tccccggcct	ccatcccggc	1440
caaagctacc	tccaggaaag	cctggagttg	gagacgtgtc	cagacctttt	agcccacca	1500
tacactcctc	cagccctcct	ccaatagcac	ccttagcccg	ggctgaaagc	acttcttcaa	1560
tatcatcaac	caattccctg	agcgcagcca	ccactcccac	agttgagaat	gaacagsctt	1620
ccctcgtttg	gtttgacaga	ggaaagtttt	atgtgacttt	tgaaggttct	tccaggggac	1680
ccagtcctct	aactatgggg	gccaggaca	ccctcccggg	tgcagcagca	ttcacagaaa	1740
ctgtcaatgc	ctacttcaaa	ggagcagatc	caagcaaatg	cattgttaag	atcacgggag	1800
aaatggtggt	gtcctttcct	gctggcatca	ccagacactt	tgccaacaac	ccatcccag	1860
ctgctctgac	ttttcgagtg	ataaattoca	gcaggttaga	gcacgtcctg	ccgaaccccc	1920
agctcctctg	ctgcgataac	acacaaaatg	atgccaatac	caaggaattc	tgggtaaaca	1980

- 4 -

tgccaaattt	gatgaccac	ctgaagaagg	tctctgaaca	aaaaccccag	gctacatatt	2040
acaatgtgga	catgctcaag	tatcaggtgt	cagcccaggg	cattcagtcc	acacctctga	2100
acttggcggg	gaactggcgc	tgtgagcctt	ccagcactga	cctgcgcata	gattataagt	2160
acaacacgga	tgccatgtcc	accgcagtgg	cccttaacaa	cgtgcagttc	ctggccccca	2220
ttgatggagg	agtgaccaag	ctccaggctg	tccttcctcc	agcagtctgg	aatgctgaac	2280
aacaaagaat	attatggaag	attcctgata	tctcccagaa	gtcagaaaat	ggaggcgtag	2340
gttctttact	ggcaagattt	caattagccg	aaggcccaag	caaaccttcc	ccactggctg	2400
tgcagttcac	gagtgaaggg	agcactctgt	ctggctgcga	cattgagctt	gtcggagcag	2460
ggtagcgggt	ttcactcatc	aagaagaggt	ttgctgcagg	aaaatacttg	gccgataact	2520
aataaaatgt	catgcaagga	ttttgaagat	ccatgtcctg	gagaactggt	gtctgagaga	2580
catatthtaa	tctggtttga	ggaaaacaaa	ccaaccgatg	tctgtacgtg	ggctctgtca	2640
gctggaaggt	cccggctttc	agccgtgatt	tcccacaccc	agtacaagga	ggatcagttc	2700
tacagtactt	acttctaggt	gtactattgt	taatggtttt	aaaatgtaat	tattgtatth	2760
gtaaactgta	ccttcattcc	agtaaggcag	ttagacacct	gagtttttagc	ttttttttcc	2820
attcctgaaa	cggatgtaat	ttaaactgcg	gtatgtaaat	ttaatagtag	tactgtcgaa	2880
tggcacaatg	cttacagaga	tacagtgcac	tttgtcaata	tataaaattt	aaatataatg	2940
ttgatagtta	ccataaaggg	ggtgccacac	atcaagaacc	ttaaatggaa	ccagaaacaa	3000
gcaagcaaac	aaacaaacaa	acaaacaaaa	ccttactttt	cttcaactcc	tattacattt	3060
tcctctagag	ctaaagaaac	ttctagcttc	ggtttagtgg	gttaaattca	gaaactatth	3120
cagaaaaaaaa	aaaaaattct	gaagttacag	catattcaaa	gagaagcatt	aattaccact	3180
tttttaaaag	cttttttttc	aaaccgcaa	tttcataaaa	atgcaaactg	tgtaaacagg	3240
gcctcttatt	tttataactt	gtgtaaaaag	ggaaaatcaa	ttcataatth	aagtttaagt	3300
agtattaaat	tatatccaag	agtgaagagg	atgttgaaat	cttacctgac	cccatgcccc	3360
ttctttgcag	tttagcaaat	gttgagattg	ctaaatcatc	agattaaagc	caacttgatt	3420
tttaaagttt	caagactttc	tgaagctgaa	ctggttaaaa	cttttgacac	attgcttgga	3480
acggaggggg	aggggcctct	ctggctccagc	acaggtacct	tgttttcttc	ctactcacia	3540
gaatcaaaac	aatgaaagtc	aagaaccaca	gaggggggaa	attagttccc	tgttcagttc	3600
aaaaggagaa	ctttaaactt	atcatttacg	tctttgggga	aggaagaaat	aagctthata	3660

- 5 -

agtgaatcc tattcacctt gttgtcctat gaatgttttc ggggtgactt taagattcat 3720
 tgtatacatg tgcgagtctc tgctattctt ggggagttga aagcagagcc aggccagtgg 3780
 ccttgaagtt cagtaaatgc cacagttctg gggcaaaggt aggcatgagg gttctgcccc 3840
 tcagcacagg aatcagagca gtgtcttgta aggtctaaag attaagtctt ccagtaagcc 3900
 acaagttatt ttgtaacaga gttggggagt tttggcactc gctgctgact ttcattttgt 3960
 atccaactca atggagtctt caactctttt caactttaga atcaaattaa tttttttttt 4020
 tttttttttt tttttacaca aggtttactc tgtgtaactg tcctggatgt tctggaactc 4080
 tttttgtaga ccaggctggc ctcgaactca gagagatcca cctgcctgtg ctccccaaagt 4140
 gctgggatta aaggcgtgtg ccaccatgcc tggcttagat taaatttttt aagtcttact 4200
 tcaccagtga gattgtgatt ggcagttggt tcgagagagc tttgtagctt aatctatggt 4260
 ctcttcaatc aatgcttgct accaaaagaa tgtccaaaat gatctatttt tcctgggaac 4320
 aattcatcta tttaaatagg ctcttgcccta gttccccaaa gcagcctgtc tttgaaggtt 4380
 tttttgaaca aaataatttt ttcacaaaaa gtttggtttt gaaatcaaaa tagagaaata 4440
 aaatgtaa at tttaaatcta atggaacatg aggaaatgaa aaaacttaag ccaatggaga 4500
 gtaaaagcag aaaaaaatga aacttaccta gaatgtgatt atattatggt tttaaagtagt 4560
 caattcatgg aaaaatattg aatattaaca caaagcatat taaaaatag taaatattac 4620
 tgtttotcat gtctttctct ttatatctta ttttatatag ttttagaatg aattggtcat 4680
 taaatacagt gtttctttcc aaagaataat tttgttgata ttgtaaaaaat gtaattaaag 4740
 atagagactt gaatagtctc taacattatc caaatgtttc taggaacca attcaaagct 4800
 gtgaagaaag cttgcaatcc ctgaattggc ttttgtgaaa tggaatgacg gtgggtaatc 4860
 tcaaaattca gacttgaata gtcagagctg aagtggggaa tgggtggttc cttctggttc 4920
 agaaaatagg tcaaaataaca gcatttgctc gcatcagga tggagatggt ggtgatgttt 4980
 ggttttactc tcgcaggctt tcgtctcctg ttgaagggtg atctgtagcc cagtgggata 5040
 agagttcatg ttctgagatg tggctcctaga caaggcaggc aaggtttcag tcatcaatac 5100
 ctatcaggtc aggttccctt ttgtctatac aaaatgggtt agctcatagc cagatggttt 5160
 gcaggacagt gagctaaatt aggacaagat tctggtttagc caaagagctg tttcctaagc 5220
 actctgattt ttttttaaag ctgatagaaa gtgtaaagt tctattttga cgacatggaa 5280
 agtatgtttt cctcttcaaa taaatccctt atttttatga aattttcaaa aataaattct 5340
 tgtttaaaat agtctgaatg ttatcatagt tggaacttgg caattactaa tttgaaattc 5400

tatgagatgt atctccagct aaaatggcaa ttccctgtat gctatctggg gctcagttta 5460
 cctctaagga agactgtcag agtgcaaatg gttttgagtg acgggaaagt caaagggcaa 5520
 atgtttgtgc ttttttcttt ttctgtctta tataacttctt cttgggtctca gaatgcaaag 5580
 tatcagagcc atagttacac acatttccac ttttaacgct tcttttgaag gaagcagatc 5640
 cacttttgcc ccgccactca tgccctgtgt gcagactcag acgagtcacct gccctcttca 5700
 cgcttttggg gtgagagggg agccatatgt aagtagtttt caagcttttc ttaatgggac 5760
 ttttcttttt ctaataaaat catgcctgga atcctgtaaa gattggtgcc tggctgtgaa 5820
 ggggcttctc cagatcctga aatatagcat cacaatacgt aatgactcc cgatggatct 5880
 cccagctctg aagacttgct cttctacttc acatgtgtag ccacgacgat cagctggcac 5940
 acagtacaat tagctgtgta gtgagtgtc cccagctatc agtcatgaaa catatcactt 6000
 tgctcaacct gtttttaaaa aagctccaaa atggtaaaaa tgcttttcag tctttgtttt 6060
 cccaataatg gtattgaggc ctaagctgat taacttcccc caaagtggta ccacagctgg 6120
 taacgacccc aatgatcctg aaaaaaatgg aatgagtacc ttgctgtttc rtttagttya 6180
 ttttgggaaa ataatccatt tgaatgtcaa gataaaaagg caccaggaaa agtcctcatt 6240
 ggaaggatta aagatgagcc tggttaagatg ttaagatgta agatgttaag atgtgttact 6300
 gtaaaaaaaaa aaagctt 6317

<210> 4
 <211> 827
 <212> PRT
 <213> Psammomys obesus

<400> 4

Met Met Glu Gly Leu Lys Lys Arg Thr Arg Lys Ala Phe Gly Ile Arg
 1 5 10 15

Lys Lys Glu Lys Asp Thr Asp Ser Thr Gly Ser Pro Asp Arg Asp Gly
 20 25 30

Met Gln Pro Ser Pro His Glu Leu Pro Tyr His Ser Lys Ala Glu Cys
 35 40 45

Ala Arg Glu Gly Gly Asn Lys Ala Ser Lys Lys Ser Asn Gly Ala Pro
 50 55 60

- 7 -

Asn Gly Phe Tyr Ala Glu Ile Asp Trp Glu Arg Tyr Asn Ser Pro Glu
 65 70 75 80

Leu Asp Glu Glu Gly Tyr Ser Ile Arg Pro Glu Glu Pro Gly Ser Thr
 85 90 95

Lys Gly Lys His Phe Tyr Ser Ser Ser Glu Ser Glu Glu Glu Glu
 100 105 110

Ser His Lys Lys Phe Asn Ile Lys Ile Lys Pro Leu Gln Ser Lys Asp
 115 120 125

Ile Leu Lys Asn Ala Ala Thr Val Asp Glu Leu Lys Ala Ser Ile Gly
 130 135 140

Asn Ile Ala Leu Ser Pro Ser Pro Val Arg Lys Ser Pro Arg Arg Ser
 145 150 155 160

Pro Gly Ala Ile Lys Arg Asn Leu Ser Ser Glu Glu Val Ala Arg Pro
 165 170 175

Arg Arg Ser Thr Pro Thr Pro Glu Leu Thr Ser Lys Lys Pro Leu Asp
 180 185 190

Asp Thr Leu Ala Leu Ala Pro Leu Phe Gly Pro Pro Leu Glu Ser Ala
 195 200 205

Phe Asp Gly His Lys Thr Glu Val Leu Leu Asp Gln Pro Glu Ile Trp
 210 215 220

Gly Ser Gly Gln Pro Val Asn Pro Ser Met Glu Ser Pro Lys Leu Ala
 225 230 235 240

Arg Pro Phe Pro Thr Gly Thr Pro Pro Pro Leu Pro Pro Lys Thr Val
 245 250 255

Pro Ala Thr Pro Pro Arg Thr Gly Ser Pro Leu Thr Val Ala Thr Gly
 260 265 270

Asn Asp Gln Ala Ala Thr Glu Ala Lys Ile Glu Lys Leu Pro Ser Ile
 275 280 285

Ser Asp Leu Asp Ser Ile Phe Gly Pro Val Leu Ser Pro Lys Ser Val

- 9 -

Leu Val Trp Phe Asp Arg Gly Lys Phe Tyr Leu Thr Phe Glu Gly Ser
 530 535 540

Ser Arg Gly Pro Ser Pro Leu Thr Met Gly Ala Gln Asp Thr Leu Pro
 545 550 555 560

Val Ala Ala Ala Phe Thr Glu Thr Val Asn Ala Tyr Phe Lys Gly Ala
 565 570 575

Asp Pro Ser Lys Cys Ile Val Lys Ile Thr Gly Glu Met Val Leu Ser
 580 585 590

Phe Pro Ala Gly Ile Thr Arg His Phe Ala Asn Asn Pro Ser Pro Ala
 595 600 605

Ala Leu Thr Phe Arg Val Ile Asn Ser Ser Arg Leu Glu His Val Leu
 610 615 620

Pro Asn Pro Gln Leu Leu Cys Cys Asp Asn Thr Gln Asn Asp Ala Asn
 625 630 635 640

Thr Lys Glu Phe Trp Val Asn Met Pro Asn Leu Met Thr His Leu Lys
 645 650 655

Lys Val Ser Glu Gln Lys Pro Gln Ala Thr Tyr Tyr Asn Val Asp Met
 660 665 670

Leu Lys Tyr Gln Val Ser Ala Gln Gly Ile Gln Ser Thr Pro Leu Asn
 675 680 685

Leu Ala Val Asn Trp Arg Cys Glu Pro Ser Ser Thr Asp Leu Arg Ile
 690 695 700

Asp Tyr Lys Tyr Asn Thr Asp Ala Met Ser Thr Ala Val Ala Leu Asn
 705 710 715 720

Asn Val Gln Phe Leu Val Pro Ile Asp Gly Gly Val Thr Lys Leu Gln
 725 730 735

Ala Val Leu Pro Pro Ala Val Trp Asn Ala Glu Gln Gln Arg Ile Leu
 740 745 750

- 10 -

Trp Lys Ile Pro Asp Ile Ser Gln Lys Ser Glu Asn Gly Gly Val Gly
 755 760 765

Ser Leu Leu Ala Arg Phe Gln Leu Ala Glu Gly Pro Ser Lys Pro Ser
 770 775 780

Pro Leu Val Val Gln Phe Thr Ser Glu Gly Ser Thr Leu Ser Gly Cys
 785 790 795 800

Asp Ile Glu Leu Val Gly Ala Gly Tyr Gly Phe Ser Leu Ile Lys Lys
 805 810 815

Arg Phe Ala Ala Gly Lys Tyr Leu Ala Asp Asn
 820 825

<210> 5
 <211> 366
 <212> DNA
 <213> Psammomys obesus

<220>
 <221> misc_feature
 <222> (305)..(305)
 <223> n = any nucleotide

<220>
 <221> misc_feature
 <222> (308)..(308)
 <223> n = any nucleotide

<220>
 <221> misc_feature
 <222> (315)..(315)
 <223> n = any nucleotide

<220>
 <221> misc_feature
 <222> (317)..(317)
 <223> n = any nucleotide

<220>
 <221> misc_feature
 <222> (327)..(327)
 <223> n = any nucleotide

<220>

- 11 -

<221> misc_feature
 <222> (339)..(339)
 <223> n = any nucleotide

<400> 5
 tcgcggatcc agacgctgcg tttgctggct ttgatgaaat ttttaatttt tcaatatcag 60
 gaatgtttta ctatgccatg aatttatggg agtcaagggt ggaaggcagg ggagaggaca 120
 cagggagtaa aggcaactgc cccaagcct tacaacctga attccatccc agagtgccta 180
 atggttgaag gacggaactg aatatctcta gctgtcctct atcctccaca gatacacagt 240
 gaatgcatca acgtaaaaaa ttacagctag aaataatgtc gtgccattca ttgtatttta 300
 cattngtnca tcttngnttt tccatantaa aaatgtctna gacataccac ttaaaaaaaaa 360
 aagctt 366

<210> 6
 <211> 442
 <212> DNA
 <213> Psammomys obesus

<400> 6
 ccctatccgc taccctggg agggacacaa aaacacattt tgtgtttttg aaaaaactga 60
 ggtcaccaga ctcttgtatt gtcttcttgg acttctctca ggaacactca ggactctccc 120
 cacacaacac cgttcttgaa ccgttctaac aaatgtttaa agtggtttcc tttgaaccac 180
 attaaattta gtttaagcag tcaccagtgg gctagcagtt ctgggttggg cagcacatct 240
 tgtacaagct cttccatctg ccaggatcac cacctctctg acttgcacat ttgtgggttc 300
 cccacagacg aatgggatga gtgaaagagt gagtatgttc tgttgggcct tcagtaacag 360
 aagactgatt cagaaagtag cacacgtcac attttctgt aggttggttt gtttagtttc 420
 atttttgatt tgtggaacaa aa 442

<210> 7
 <211> 189
 <212> DNA
 <213> Psammomys obesus

<400> 7
 tgagagtcca tctcagctta tttcattgag atgttttgat taagaagtat gactagatta 60
 aaaaattcta tatagcttgg cattgttgat agtttatata tttcactgat ttctgggtccc 120
 ttgaaagtta cttgggtgatc aacatagtgt agtgaaagga ttgggatgga cattaaaaaa 180
 aaaaagctt 189

- 12 -

<210> 8
 <211> 378
 <212> DNA
 <213> Psammomys obesus

<220>
 <221> misc_feature
 <222> (4)..(4)
 <223> n = any nucleotide

<220>
 <221> misc_feature
 <222> (13)..(13)
 <223> n = any nucleotide

<400> 8
 tggntactct tgnaagcacc ttgaaagttc agcctgctaa cttacctttt tagctttaga 60
 ttgcttagat attcaaatga gagtgtggtg caaatcctga ttacaaggag tttgagtttg 120
 gagtgattgg caatgcactt gtgaggctgt gtgcctatgg tcctaggact taggaggcag 180
 ggatagaagg accaggtgct gaaagacagc cttggctagt tagtggacag atacataaat 240
 gtactgcatg agattctttc agaataacaa cctcctttta aagaagttac ttctgacatg 300
 gaatctgttg cctgcttttg gatcactacc ccctgggtggg acacctttgc cagaccatgg 360
 aggaagaact gtcttgat 378

<210> 9
 <211> 342
 <212> DNA
 <213> Psammomys obesus

<220>
 <221> misc_feature
 <222> (27)..(27)
 <223> n = any nucleotide

<220>
 <221> misc_feature
 <222> (341)..(342)
 <223> n = any nucleotide

<400> 9
 aacgtgagct ttttgaagg cccaganaat ttaaggaaag tgtcccggca aatcctgatt 60
 acaaggagtt tgagtttggg gtgattggca atgcacttgt gaggtgtgtg gcctatggtc 120

- 13 -

ctaggactta ggaggcaggg atagaaggac caggtgctga aagacagcct tggctagtta 180
 gtggacagat acataaatgt actgcatgag attcttttcag aataacaacc tcctttttaa 240
 gaagttactt ctgacatgga atctgttgcc tgcttttggga tcactacccc ctggtgggac 300
 acctttgccca gaccatggag gaagaactgt cttgatggga nn 342

<210> 10
 <211> 19
 <212> DNA
 <213> artificial sequence

<220>
 <223> primer

<400> 10
 gtagactgcg taccaattc 19

<210> 11
 <211> 19
 <212> DNA
 <213> artificial sequence

<220>
 <223> primer

<400> 11
 gacgatgagt cctgagtaa 19

<210> 12
 <211> 24
 <212> DNA
 <213> artificial sequence

<220>
 <223> AGT-119 (set 1) forward primer

<400> 12
 ggattatcgt gaccagatag gagc 24

<210> 13
 <211> 21
 <212> DNA
 <213> artificial sequence

<220>
 <223> AGT-119 (set 1) reverse primer

<400> 13
 acgcatcttg ttgggctaata g 21

- 14 -

<210> 14
<211> 20
<212> DNA
<213> artificial sequence

<220>
<223> AGT-119 (set 2) forward primer

<400> 14
cgcaaccaaa ttagccagtg 20

<210> 15
<211> 23
<212> DNA
<213> artificial sequence

<220>
<223> AGT-119 (set 2) reverse primer

<400> 15
gcatcttggtt gggctaata ga cat 23

<210> 16
<211> 19
<212> DNA
<213> artificial sequence

<220>
<223> AGT-120 forward primer

<400> 16
accagatgc tggctgact 19

<210> 17
<211> 22
<212> DNA
<213> artificial sequence

<220>
<223> AGT-120 reverse primer

<400> 17
ctggccacca gtcagtgaat aa 22

<210> 18
<211> 28
<212> DNA
<213> artificial sequence

<220>
<223> AGT-121 forward (insertion) primer

<400> 18

- 15 -

aaaacatgag agaagccata ctaattca 28

<210> 19
<211> 31
<212> DNA
<213> artificial sequence

<220>
<223> AGT-121 reverse (deletion) primer

<400> 19
cacaaaacat gagatactaa ttcataagtg a 31

<210> 20
<211> 24
<212> DNA
<213> artificial sequence

<220>
<223> AGT-121 reverse primer

<400> 20
tgaaaccaag atagcacaaa cgaa 24

<210> 21
<211> 22
<212> DNA
<213> artificial sequence

<220>
<223> AGT-122 forward primer

<400> 21
catcccagag tgcctaattg tt 22

<210> 22
<211> 25
<212> DNA
<213> artificial sequence

<220>
<223> AGT-122 reverse primer

<400> 22
acgttgatgc attcactgtg tatct 25

<210> 23
<211> 20
<212> DNA
<213> artificial sequence

<220>

- 16 -

<223> AGT-422 forward primer

<400> 23
cagtcaccag tgggctagca 20

<210> 24
<211> 20
<212> DNA
<213> artificial sequence

<220>
<223> AGT-422 reverse primer

<400> 24
cctggcagat ggaagagctt 20

<210> 25
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> AGT-123 forward primer

<400> 25
gcttggcatt gttgatagtt tatatatttc 30

<210> 26
<211> 30
<212> DNA
<213> artificial sequence

<220>
<223> AGT-123 reverse primer

<400> 26
cactacacta tgttgatcac caagtaactt 30

<210> 27
<211> 21
<212> DNA
<213> artificial sequence

<220>
<223> AGT-504 forward primer

<400> 27
gaatctgttg cctgcttttg g 21

<210> 28
<211> 20
<212> DNA

- 17 -

<213> artificial sequence

<220>
<223> AGT-504 reverse primer

<400> 28
ctccatggtc tggcaaaggt 20

<210> 29
<211> 22
<212> DNA
<213> artificial sequence

<220>
<223> Beta-actin forward primer

<400> 29
gcaaagacct gtatgccaac ac 22

<210> 30
<211> 23
<212> DNA
<213> artificial sequence

<220>
<223> Beta-actin reverse primer

<400> 30
gccagagcag tgatctcttt ctg 23

<210> 31
<211> 25
<212> DNA
<213> artificial sequence

<220>
<223> Beta-actin probe

<400> 31
tccggtccac aatgcctggg aacat 25

<210> 32
<211> 19
<212> DNA
<213> artificial sequence

<220>
<223> Cyclophilin forward primer

<400> 32
cccaccgtgt tcttcgaca 19

- 18 -

<210> 33
<211> 20
<212> DNA
<213> artificial sequence

<220>
<223> Cyclophilin reverse primer

<400> 33
ccagtgctca gagcacgaaa 20

<210> 34
<211> 23
<212> DNA
<213> artificial sequence

<220>
<223> Cyclophilin probe

<400> 34
cgcgtctcct tcgagctggt tgc 23

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU02/01405

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl. ⁷ : C07H 21/02, 21/04, C07K 14/47, A61K 38/17, 48/00, A61P 3/00, 3/06, C12Q 1/68		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) ANGIS Keywords: Psammomys obesus, stomach, liver, hypothalamus		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GenBank Acc. No.: BB257743 RIKEN full-length enriched 7 days neonate cerebellum <u>Mus musculus</u> , 6 July 2000	1, 7
X	GenBank Ac. No.c: BG797393 Kaestner ngn3 wt <u>Mus musculus</u> , 18 May 2001	1, 7
X	GenBank Acc. No.: AI661150 Soares mouse lymph node NbMLN <u>Mus musculus</u> , 7 May 1999	1, 7
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input type="checkbox"/> See patent family annex		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
Date of the actual completion of the international search 8 November 2002		Date of mailing of the international search report 13 NOV 2002
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustrialia.gov.au Facsimile No. (02) 6285 3929		Authorized officer R.L. POOLEY Telephone No : (02) 6283 2242

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU02/01405**Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos :
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Claims 1-12, 14-18 are in fact directed to eight different inventions, namely,
Sequences ID Nos. 1, 2, 3, 5, 6, 7, 8, 9, which are isolated nucleic acid molecules differentially expressed.

There are further inventions as a result of and corresponding to
(continued on separate sheet)

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU02/01405

Supplemental Box

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: II

each of the sequences having at least about 30% homology to Sequences ID Nos. 1, 2, 3, 5, 6, 7, 8, 9.

Claim 13 is directed to yet another different invention, namely, isolated nucleic acid molecule encoding the amino acid sequence of SEQ ID No:4

There are no common structural features between these sequences to constitute a special technical feature. The only apparent single inventive concept to link them is that the genes of the invention are differentially expressed in the hypothalamus, stomach or liver and proposed to be useful as therapeutic and diagnostic agents for obesity/type 2 diabetes. However, differentially expressed genes for obesity/type 2 diabetes are *a posteriori* known (see for examples: Watson PM, et.al., *Am J Physiol Endocrinol Metab*, August 2000, 279 (2) E356-65, Berraondo B, et.al., *Int. J Obes Realt Metab Disord*, February 2000, 24(2), 156-63, Ziotopoulou M, et.al., *Am J Physiol Endocrinol Metab*, October 2000, 279 (4) E838-45).

Please note that the search results provided are selected to be representative rather than comprehensive because of, for example, the low homology suggested by the claims.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU02/01405

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	GenBank Acc. No.: AC092947 Homo sapiens chromosome 3 clone RP11-54801, 28 September 2002	1, 2
X	"PCR amplification of the Irish potato famine pathogen from historic specimens", Ristaino J.B., Grove C.T., Parra G.R., NATURE 411 (6838): 695-697 (2001) (& EMBL Acc: AY003913 Phytophthora infestans isolate 94-1 NADH dehydrogenase subunit 4 pseudogene, partial sequence, 14 September 2000)	1, 3
X	"PCR amplification of the Irish potato famine pathogen from historic specimens", Ristaino J.B., Grove C.T., Parra G.R., NATURE 411 (6838): 695-697 (2001) (& EMBL Acc: AY003912 Phytophthora infestans isolate US920141 NADH dehydrogenase subunit 4 gene, partial compounds, 14 September 2000)	1, 3
P, X	GenPept AAH17596 Mus musculus, similar to hypothetical protein DKFZp761D221, clone MGC:27557, IMAGE:4482298, mRNA, complete compounds, 26 November 2001	1, 3, 13, 19
P, X	GenPept CAB66496 Homo sapiens mRNA, cDNA DKFZp761D221, complete compounds, 9 July 2002	1, 3, 13, 19
P, X	GenBank Acc. No.: AC116063 Rattus norvegicus clone CH230-137P24 Sequencing in progress, 68 unordered pieces, 8 October 2002	1, 5
X	"Sulfurospirillum arcachonense sp. nov., a new microaerophilic sulfur-reducing bacterium", Finster K., Liesack W., Tindall B.J., Int. J. Syst. Bacteriol. 47:1212-1217 (1997) (& EMBL Acc: SDY13671 Sulfospirillum deleyianum 16S rRNA gene, partial 29 October 1997)	1, 5
X	WO 99 67282 A2 (CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)) 29 December 1999. See Sequence ID No.42 on page 30 (& GenBank Acc: AX008344 Sequence 42 from Patent WO9967282, 6 September 2000)	1, 6
P, X	GenBank Acc. No.: AC113647 Rattus norvegicus clone CH230-325A20 Sequencing in progress, 66 unordered pieces, 18 September 2002	1, 6
X	EMBL Acc: AC020950 Homo sapiens chromosome 19 clone LLNLR-244B2 complete sequence, 14 January 2000	1, 7
P, X	GenBank Acc. No.: AL669981 Mus musculus chromosome 4 clone RP23-335B9 complete sequence, 24 August 2002	1, 8
X	EMBL Acc: APGD57 Artificial DNA sequence (pGD57) of pBR322 derived cloning vector 8 July 1992	1, 9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/AU02/01405

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		Patent Family Member					
WO	99/67282	AU	42707/99	EP	1090119	FR	2780405
		JP	2002518035	US	2002132289		
							END OF ANNEX